Next Article in Journal
A Novel Angiotensin-I-Converting Enzyme (ACE) Inhibitory Peptide from Takifugu flavidus
Previous Article in Journal
Surface Glucan Structures in Aeromonas spp.
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Marine Drugs
Volume 19
Issue 11
10.3390/md19110650
marinedrugs-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

In Silico Prediction of Steroids and Triterpenoids as Potential Regulators of Lipid Metabolism

by
Valery M. Dembitsky
Centre for Applied Research, Innovation and Entrepreneurship, Lethbridge College, 3000 College Drive South, Lethbridge, AB T1K 1L6, Canada
Mar. Drugs 2021, 19(11), 650; https://doi.org/10.3390/md19110650
Submission received: 25 October 2021 / Revised: 12 November 2021 / Accepted: 19 November 2021 / Published: 22 November 2021
Browse Figures
Review Reports Versions Notes

Abstract

:
This review focuses on a rare group of steroids and triterpenoids that share common properties as regulators of lipid metabolism. This group of compounds is divided by the type of chemical structure, and they represent: aromatic steroids, steroid phosphate esters, highly oxygenated steroids such as steroid endoperoxides and hydroperoxides, α,β-epoxy steroids, and secosteroids. In addition, subgroups of carbon-bridged steroids, neo steroids, miscellaneous steroids, as well as synthetic steroids containing heteroatoms S (epithio steroids), Se (selena steroids), Te (tellura steroids), and At (astatosteroids) were presented. Natural steroids and triterpenoids have been found and identified from various sources such as marine sponges, soft corals, starfish, and other marine invertebrates. In addition, this group of rare lipids is found in fungi, fungal endophytes, and plants. The pharmacological profile of the presented steroids and triterpenoids was determined using the well-known computer program PASS, which is currently available online for all interested scientists and pharmacologists and is currently used by research teams from more than 130 countries of the world. Our attention has been focused on the biological activities of steroids and triterpenoids associated with the regulation of cholesterol metabolism and related processes such as anti-hyperlipoproteinemic activity, as well as the treatment of atherosclerosis, lipoprotein disorders, or inhibitors of cholesterol synthesis. In addition, individual steroids and triterpenoids were identified that demonstrated rare or unique biological activities such as treating neurodegenerative diseases, Alzheimer’s, and Parkinson’s diseases with a high degree of certainty over 95 percent. For individual steroids or triterpenoids or a group of compounds, 3D drawings of their predicted biological activities are presented.

Graphical Abstract

1. Introduction

Lipids are a complex name for many metabolites of natural origin, and they are combined into various groups according to a common physical property, hydrophobicity, that is, insolubility in water [1,2,3,4]. However, this definition is currently not entirely correct, since some groups, phospholipids or sphingolipids and some others, manifest themselves as amphiphilic compounds; that is, they can dissolve both in polar substances and in non-polar solvents [5,6,7,8].
Lipids play an important role in the body in storing energy and are components of biological membranes, steroid hormones, bile acids, and vitamins. They come from food or de novo synthesis in the liver. Fatty acids, stored primarily as triglycerides, are the main source of energy for the muscles and heart. However, the overproduction and accumulation of triglycerides in adipose tissue and other tissues are closely associated with metabolic disorders in humans. Disorders of lipid metabolism lead to the development of many diseases, including atherosclerosis, which occurs because of a violation of cholesterol homeostasis and is closely associated with atherosclerosis [9,10]. In addition, estrogen and estrogen receptors are well-known regulators of several aspects of metabolism, including glucose and lipid metabolism, and impairment of estrogen signaling is associated with the development of metabolic diseases [11].
The regulation of lipid metabolism is of interest primarily in the context of the regulation of energy flow and the way of its integration with other energy sources in tissues. A special role in the regulation of lipid metabolism is played by hormones such as adrenaline and norepinephrine, glucagon, glucocorticoids, hormones of the anterior pituitary gland, as well as thyroxine and sex hormones [12,13,14,15,16,17,18,19,20].
This review is devoted to natural, semi-synthetic and synthetic steroids, and triterpenoids isolated from plants, fungi, marine invertebrates, and synthesized in various laboratories around the world. The presented class of molecules differs from many other steroids or triterpenoids that exhibit a wide range of biological activities aimed at lowering cholesterol by inhibiting cholesterol synthesis or other activities associated with these processes.

2. Aromatic Steroids Derived from Natural Sources

The most famous natural monoaromatic steroids that are of some practical interest in terms of regulators of lipid metabolism are estrone (1), estradiol (2), estriol (3), and equilin (4). The chemical structures of these aromatic steroids are shown in Figure 1. It is known that estrone is a minor female sex hormone, which was discovered in the 1920s from the urine of pregnant women independently by two groups of scientists from Germany and the United States, biochemist Adolph Butenandt and American scientists Edward Doisy and Edgar Allen, respectively [21,22,23,24,25,26,27,28]. Later, Adolf Frederik Johann Butenandt from the Institute of Chemistry in Götting (Germany) received the Nobel Prize in Chemistry in 1939 for the discovery of this hormone.
Estrone, or (8R,9S,13S,14S)-3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one (1), is produced in vivo from androstenedione and/or testosterone via estradiol. The above-mentioned estrogens show estrogenic activity with various variations [29,30], although changes in the structure of estrogens D ring may also demonstrate anticancer activity [31]. The presence of female sex hormonal (1–4) estrogens was first detected in plants in 1926 by Dohrn and co-workers [32] and then, in the 1930s, simultaneously by Butenandt and Jacobi [26] and Skarzynski [33]. Recently, Janeczko and Skoczowski [34] published a survey in which they summarized the data on the presence of mammalian sex hormones and their physiological role in plants. These hormones, such as 3,17β-dihydroxy-1,3,5(10)-estratriene, rosterone, testosterone, or progesterone, were present in 60–80% of the plant species investigated. Butenandt and Jacobi [26] isolated estrone (1) from seeds and pollen of Hyphaene thebaica, Glossostemon bruguieri. Glycyrrhiza glabra, Malus pumila, Phoenix dactylifera, Ph. vulgaris, Punica granatum, Salix caprea, and Salix sp. The chemical structures of steroids and triterpenoids are shown in Figure 1, and biological activity is shown in Table 1.
From the 1930s to the present, more than 15,000 articles have been devoted to various issues of estrone and its derivatives, and more than 200 reviews summarize the data on the activity of this hormone. Estrone (1) and estradiol (2) and their derivatives (3–10) are the main natural estrogens found in humans and are involved in estrogen metabolism [35,36,37,38]. Endogenous estrogens in humans demonstrate a wide range of biological activities and are involved in the regulation of lipid metabolism, which has been the subject of tens of thousands of articles, reviews, and books. Additionally, in this short paragraph, we will not list and discuss this topic, but in Table 1, we give a short list of the main biological activities that aromatic steroids show.
Aromatic steroids found in animals and humans are also produced by some marine invertebrates and are found in the extracts of certain plants and fungi, as well as in marine sediments. Thus, the extract of bark from the main wooden rod of ketapang Terminalia catappa (family Combretaceae) contained estrone (1), estriol (3), equilin (4), equilin sulfate (5), and (11) [39]. The ethanol extract of leaves of T. catappa shows antimicrobial activity against Escherichia coli, Staphylococcus aureus, and Candida albicans, as well as antifungal activity against Epidermophyton floccosum and C. albicans [40,41,42]. In addition, extracts of leaves and roots and other parts have been studied for many medicinal properties and have shown antidiabetic, wound healing, anti-inflammatory, anticancer, antimicrobial, hepatoprotective, and antioxidant activities [43]. Unusual withanolide (20S,22R)-1,6β,17α,27-tetrahydroxy19-norwitha-1,3,5(10),24-tetraenolide, named jaborosalactone 7-(12), was isolated from the leaf extracts of Juborosa leucotricha [44].
The steroid 24,26-cyclo-19-norcholesta-1,3,5(10),22-tetraen-3-ol (13) is characterized by the presence of an aromatic A ring containing a cyclopropane ring in the side chain was isolated from the Hainan soft coral Dendronephthya studeri [45]. The ring A-aromatic bile acid 3-hydroxy-19-norchola-1,3,5(10),22-tetraen-24-oic acid (14) was isolated from methanol extract of the marine sponge Sollasella moretonensis, collected from the seabed of northern Queensland, Australia [46]. Commenting on the release of this unusual lipid, the authors point out that aromatic steroids are more typical for plants and less so for marine invertebrates or higher animals. A 4-hydroxy-6-oxopregnane-3-glycoside with an aromatic ring A containing the sugar 6′-deoxy-L-β-altropyranose-4′-acetate named hapaioside (15) was found in the extract of a Pohnpei, a tube sponge, Cribrochalina olemda from the family Niphatidae [47]. The activity of this glycoside has not been determined, although it is known that this marine sponge contains cyclic peptides called kapakahines, some of which show cytotoxicity against P388 murine leukemia cells [48]. Structurally similar to hapaioside, 3-(4-O-acetyl-6-deoxy-β-galactopyranosyloxy)-19-norpregna-1,3,5(10),20-tetraene (16) was isolated from bush coral Alcyonium gracillimum (syn. Scleronephthya gracillimum), which was collected from the Gulf of Sagami, Japan [49].
Monoaromatic B ring steroids are rare natural lipids found predominantly in the mushroom kingdom and are also present in marine sediments or oils. Thus, phycomysterol A (17) and C (18), which possess a unusual natural 19-norergostane skeleton with an aromatic B ring, are synthesized by a filamentous fungus Phycomyces blakesleeanus (order Mucorales, the phylum Zygomycota) [50]. In addition, phycomysterol A showed antiviral inhibition at a concentration of 0.64 µg per well (200 µL) and showed (IC50 = 5.0 µg/mL) against both mouse lymphomas (IC50 = 10 µg/mL) and against the three human cell lines, A549 (lung carcinoma), HT29 (colon carcinoma), and MEL28 (melanoma) human cell lines.
Pathogenic fungus Gibberella zeae (syn. Fusarium roseum) is a worldwide parasite that can produce a wide variety of steroids and synthesized unusual (22E,24R)-1(10→6)-abeoergosta-5,7,9,22-tetraen-3α-ol (19), which was isolated from the cultures of Gibberella zeae, an endophytic fungus isolated from the marine green alga Codium fragile [51]. This compound showed significant cytotoxicity toward murine colorectal CT26 and human leukemia K562 cancer cell lines. An aromatic B ring called topsentisterol E1 (20) was isolated from bioactive fractions of a marine sponge Topsentia sp. [52]. The presence of this unusual steroid may indicate that it is synthesized by the endophytic fungus, which is a symbiont in this sponge species.

Comparison of Biological Activities of Natural Aromatic Steroids

It is known that the chemical structure of both natural and synthetic molecules predetermines biological activity, which makes it possible to analyze the structure–activity relationships (SAR). This idea was first proposed by Brown and Fraser more than 150 years ago, in 1868 [53], although, according to other sources, SAR originates from the field of toxicology, according to which Cros in 1863 determined the relationship between the toxicity of primary aliphatic alcohols and their solubility in water [54]. More than 30 years later, Richet in 1893 [55], Meyer in 1899 [56], and Overton in 1901 [57] separately found a linear correlation between lipophilicity and biological effects. By 1935, Hammett [58,59] presented a method of accounting for the effect of substituents on reaction mechanisms using an equation that considered two parameters, namely the substituent constant and the reaction constant. Complementing Hammett’s model, Taft proposed in 1956 an approach for separating the polar, steric, and resonance effects of substituents in aliphatic compounds [60]. Combining all previous developments, Hansch and Fujita laid out the mechanistic basis for the development of the QSAR method [61], and the linear Hansch equation and Hammett’s electronic constants are detailed in the book by Hansch and Leo published in 1995 [62].
Some well-known computer programs can, with some degree of reliability, estimate the pharmacological activity of organic molecules isolated from natural sources or synthesized compounds [63,64,65]. It is known that classical SAR methods are based on the analysis of (quantitative) structure–activity relationships for one or more biological activities using organic compounds belonging to the same chemical series as the training set [66].
The computer program PASS, which has been continuously updating and improving for the past thirty years [67], is based on the analysis of a heterogeneous training set included information about more than 1.3 million known biologically active compounds with data on ca. 10,000 biological activities [68,69]. Chemical descriptors implemented in PASS, which reflect the peculiarities of ligand–target interactions and original realization of the Bayesian approach for 18 elucidations of structure–activity relationships, provide the average accuracy and predictivity for several thousand biological activities equal to about 96% [70]. In several comparative studies, it was shown that PASS outperforms in predictivity some other recently developed methods for estimation of biological activity profiles [71,72]. Freely available via the Internet, the PASS Online web service [73] is used by more than thirty thousand researchers from almost a hundred countries to determine the most promising biological activities for both natural and synthetic compounds [74,75,76]. To reveal the hidden pharmacological potential of the natural substances, we have successfully been using PASS for the past fifteen years [77,78,79,80].
In the current study, we obtained PASS predictions for about one hundred steroids and triterpenoids produced by different living organisms. PASS estimates are presented as Pa values, which correspond to the probability of belonging to a class of “actives” for each predicted biological activity. The higher the Pa value is, the higher the confidence that the experiment will confirm the predicted biological activity [78,80].
The study of the biological activity of aromatic steroids using the PASS program showed that all steroids presented in Table 1 can be divided into two groups. The first group includes steroids that show antiovulation activity with a high degree of reliability, and the second group includes steroids for which antihypercholesterolemic activity is dominant. The first group includes aromatic steroids numbered 7, 9, 1, 8, and 10 with over 92.5 percent confidence, although the second group includes steroids 6, 11, 13, 14, 15, and 19 with over 94.6 percent confidence, according to PASS.
A 3D graph of the predicted and calculated activities of aromatic steroids belonging to the first group is shown in Figure 2. From the first group of steroids that are inhibitors of ovulation, 2-hydroxyestrone (7) can be distinguished, which has a confidence level of more than 95%, and its predicted activities are presented in Figure 3. Additionally, 3D graphs that demonstrate the predicted pharmacological activity were obtained using the Origin Pro 2021 graphical program. The program analyzes the data obtained by the PASS program and builds graphs that are given in this publication.
Among the second group of aromatic steroids that demonstrate strong antihypercholesterolemic activity, and a 3D graph of predicted and calculated antihypercholesterolemic activity is shown in Figure 4; the strongest steroid is estrone glucuronide (6), and a 3D graph of its predicted pharmacological activities is shown in Figure 5.

3. Natural, Semi-, and Synthetic Steroid Phosphate Esters

Steroid phosphate esters are rare lipid molecules that can form the building blocks of biological membranes and have been found more recently in starfish extracts. So, for the first time, steroid phosphates were discovered more than a quarter of a century ago by Italian scientists from the University of Frederico II, in the city of Napoli. Unique steroids were isolated from the extract of the polar lipids of the starfish Tremaster novaecaledoniae, which was collected at a depth of 530 m of New Caledonia [110]. The isolated phosphated steroid glycosides were called tremasterols A and C, and their structures were identified as 3β-O-sulphated, 6α-O-phosphated, and 16β-O-acetylated groupings on a steroidal skeleton (21, 22, and 23).
Synthetic steroids, such as testosterone 17β-phosphate (24), cortisol 21-phosphate (25), and cholesterol 3β-phosphate (26), were chosen by us for comparison of biological activity with the activity of steroids isolated from marine invertebrates [111]. Testosterone 17β-phosphate (24) is an androgen and belongs to the class of anabolic steroids and is used for intramuscular injection, and it is a substrate for phosphatases in the phosphatase pool of the prostate [112]. Cortisol 21-phosphate (25) refers to the glucocorticoid class of hormones, and it functions to increase blood sugar levels through gluconeogenesis and to promote the metabolism of fats, proteins, and carbohydrates, and it is a substrate for alkaline phosphatase and is used for an enzyme immunoassay for human chorionic gonadotropin, human growth hormone, and α-fetoprotein and estradiol [113]. Cholesterol 3β-phosphate (26) promotes normalization of blood pressure and plays an important role in atherogenesis [114,115].
Two novel cholesterol-lowering agents called sodium ascorbic campestanol phosphate (27) and sodium ascorbic sitostanol phosphate (28) were synthesized, and their properties were studied [116]. Using Western blot analysis of P-GP expression, it was shown that changes in mdr-1 gene expression lead to correlating changes in P-GP protein expression. More recently, two steroid phosphate esters (29 and 30, structures see on Figure 6 and activities on Table 2) have been synthesized, acting as inhibitors of cholesterol biosynthesis. Methods of treating or preventing various diseases, conditions, and disorders by administering these steroids or compositions are also provided [117]. Estradiol phosphate (31) is ester of estrogen with phosphoric acid and acts as a prodrug of estradiol in the human body. In medical practice, both drugs can be used to treat prostate cancer [118].

Comparison of Biological Activities of Steroid Phosphate Esters

According to PASS, antihypercholesterolemic activity is characteristic of all steroid phosphate esters presented in Table 2 with varying degrees of confidence. In addition, all steroids are inhibitors of cholesterol synthesis, except for steroid 31. However, some lipid steroidal molecules such as 21–23 can be agents for wound healing and hepato-protectors with a high degree of certainty, and steroids 23–28 and 31 also demonstrate the properties of a neuroprotective agent with a high degree of certainty from 90 to 98%.
Steroid phosphate esters are of great practical interest in medicine, as they are wound healing agents. The confidence level of steroid 21 is 97.5%. Figure 7 shows the 3D graph of biological activities with a dominant property as a wound healing agent.
The sitostanol derivative (30) was synthesized by scientists from British Columbia (Canada) as a strong inhibitor of cholesterol synthesis, and as shown by the PASS data, this lipid molecule is in fact an excellent drug for the treatment of atherosclerosis. The wide range of biological activities of the sitostanol derivative (30) is shown in Figure 8.

4. Highly Oxygenated Natural Steroids and Triterpenoids

Highly oxygenated steroids are a large group of steroids and triterpenoids found in plant, fungal, and invertebrate extracts, and many of them exhibit a wide range of biological activities. This group of lipids includes secosteroids, epoxy steroids and peroxy steroids, and triterpenoids, which demonstrate a high degree of activity as potential regulators of lipid metabolism [119,120,121,122,123].

4.1. Secosteroids Derived from Marine and Terrestrial Sources

Secosteroids are a large group of natural steroidal hormones with a so-called ‘broken’ ring by oxidation of rings A, B, C, or D. Typical representatives of secosteroids are fat-soluble vitamins of group D [124,125,126,127]. Secosteroids are found in plant and animal extracts, produced by fungi, and found in marine invertebrates and algae [121,128,129,130].
Two secosterols, 3β-hydroxy-8α,9α-oxido-8,9-secoergosta-7,9(11),22-triene (32) and 3β-hydroxy-8α,9α-oxido-8,9-secoergosta-7,22-dien-12-one (33), named tylopiol A and B, respectively, were isolated from the fresh fruit bodies of fungus Tylopilus plumbeoviolaceus [131]. The other two steroids, named gloeophyllin J (34) and I (35), have been isolated from the solid cultures of North American wood-rotting fungi Gloeophyllum abietinum. Both compounds showed cytotoxic activity against human cancer cell lines K562 and HCT116 [132]. The chemical structures of steroids are shown in Figure 9 and the biological activity is shown in Table 3.
7-Oxasteroid (36) was isolated and characterized from the culture of Aspergillus ochraceus EN-31. This endophytic fungus is found and isolated from the marine brown alga Sargassum kjellmanianum (Dalian coastline, China) [133]. Compound 36 has been previously reported from a Penicillium sp. [134], and it displayed cytotoxic activity against NCI-H460, SMMC-7721, and SW1990 cell lines with IC50 values of 12.1, 16.9, and 67.6 μM, respectively [133].
Secosteroid (37) has been determined in extracts of Australian soft coral Sinularia sp. [135,136], and other octocoral Sinularia leptoclados are sources of bioactive 9,11-secosteroids and steroid 3,11-dihydroxy-9,11-secogorgost-5-en-9-one (38), which showed the highest peroxisome proliferator-activated receptor (PPAR) activity with an IC50 value of 8.3 μM for inhibiting human breast adenocarcinoma cell (MCF-7) growth. In addition, this steroid modulated the expression of various PPAR-regulated downstream biomarkers, including cyclin D1, cyclin-dependent kinase, B-cell lymphoma 2 (Bcl-2), p38, and extracellular-signal-regulated kinase [137,138].
Vitamin D2, known as ergocalciferol or 9,10-seco-(5Z,7E)-5,7,10(19),22-ergostatetraene-3β-ol (39), is the main one that is used in human nutrition [139]. All forms of vitamin D were found in mushrooms (brown Italian cremini, chanterelle, enoki, maitake, morel, shiitake, oyster, portobello, and white button mushrooms) and yeast [140,141,142,143,144,145]. Secosteroid, 3,11-dihydroxy-5,6-epoxy-9,11-secocholestan-9-one (40), was found and identified from extracts of the Taiwanese soft coral Cespitularia taeniata [146].

Comparison of Biological Activities of Secosteroids

Among the secosteroids shown in Figure 9, which show activity as regulators of lipid metabolism, the most interesting is lipid molecule number 40, which has aAntihypercholesterolemic activity with a confidence level of 97.7 percent. Figure 10 shows the 3D graph of the predicted pharmacological activities of this steroid. Ergocalciferol (39) or vitamin D2 is also of great interest, as PASS showed strong antiparkinson activity with a confidence level of 96.0%. The full spectrum of the predicted pharmacological activities of ergocalciferol is shown in the 3D graph in Figure 11.

4.2. Natural Epoxy Steroids Derived from Marine Sources

α,α-epoxy- and/or β,β-steroids are found in lipid extracts of marine invertebrates, including sponges, soft corals, starfish, and nudibranchs (Mollusca) [123,155,156,157,158,159]. Two cytotoxic epoxysteroids, 5α,6α-epoxystigmasta-7,22-en-3β-ol (41) and 5α,6α-epoxystigmasta-7-en-3β-ol (42) were isolated from the ethanolic extract of the marine sponge Ircinia aruensis [160]. The chemical structures of steroids are shown in Figure 12 and the biological activity is shown in Table 4. Topsentisterol B4 (43), epoxy steroid with the β- and α-hydroxyl groups at position 3 and 7, respectively, were present in the extract of the far eastern sponge of Topsentia sp. [161]. (24E)-5α,6α-epoxystigmasta-7,24(28)-dien-3β-ol (44) was isolated from the South China Sea sponge Phyllospongia foliascens without studying the biological activity [162]. Triterpene glycoside, eryloside U (45) with be the 7,8-epoxide group was isolated from the sponge Erylus goffrilleri collected near Arresife-Seko Reef (Cuba) [163].
Unusual 17β,20β-epoxy-23,24-dimethylcholest-5-ene-3β,22-diol (46) was found in the Indian Ocean soft coral Sarcophyton crassocaule [164].
Two diol 22,23-epoxy steroids have been isolated from the marine sponge Axinella cf. bidderi, 17α-hydroxy-22β,23β-epoxycholest-5-en-3β-ol (47) and 17α-hydroxy-22β,23β-epoxy-24-methylcholest-5-en-3β-ol (48). Isolated steroids showed activity against prostate, ovary, pancreas, colon, and lung cell lines in vitro [165].

Comparison of Biological Activities of α,β-Epoxy Steroids Derived from Marine Sources

Comparing the data from the PASS obtained for the α, β-epoxy steroids presented in Table 4, it can be concluded that there are no outstanding steroids with lipid metabolism regulator properties; then, we present in Figure 13 a comparative 3D graph for this subgroup of steroids.
For a comparative graphic characterization of α, β-epoxy steroids, we selected steroids numbered 42, 44, and 48. All these lipids are characterized by the property of regulators of lipid metabolism with dominant antihypercholesterolemic activity. According to PASS data, steroids 42 and 44 also show a high level of anticancer activity, while steroid 48 is additionally characterized by neuroprotective properties.

4.3. Peroxy-Type Steroids Derived from Natural Sources

Natural and/or synthetic compounds containing a peroxy group (R-O-O-R) are called peroxides [166,167,168,169,170,171,172]. Natural peroxides represent a rather large group of compounds that many microorganisms produce, and they have also been found in plants, mushrooms, animals, and marine invertebrates [166,167,168]. Peroxy steroids are a small group of natural lipids, mainly found in leaves, roots, and bark of plants, and are produced by fungal endophytes and are found in mushrooms [166,167,173].

4.3.1. Steroid Endoperoxides

Astropecten polyacanthus starfish extract has significant cytotoxic effects and contains an unusual peroxy steroid called astropectenol B (49) was isolated from a methanol extract of this starfish [174].
Cytotoxic steroid, (3,5,8,24R,25R)-epidioxy-24,26-cyclocholesta-6,9(11)-dien-3-ol (50) was identified from marine sponge Tethya sp. [175]. (3,5,8,24R)-Epidioxy-24-methylcholest-6-en-3-ol (51) was detected in MeOH extract of the marine sponge Luffariella cf. variabilis [176], and 22,23-dihydro-5,8-epidioxystigmast-6-en-3-ol (52) was found in the marine sponges Luffariella cf. variabilis and Tethya sp. and sea squirt Dendrodoa grossularia [175,176,177,178].
Fuscoporianol D (53) was found in field-grown mycelia of fungus Inonotus obliquus (family Hymenochaetaceae) [179]. Ergosterol peroxide 3-O-β-D-glucopyranoside (54) produced by fungus Tremella fuciformis [180] and same compound was detected in the fruiting bodies of the Chinese toxic woodland mushroom Naematoloma fasciculare [181]. Endoperoxy steroid 55 was found in popular mushroom in Japan, Buna shimeji and in oyster fungus Pleurotus ostreatus [182]. Two endoperoxy glycosides (55 and 56) were found in ethanol extracts of the fungus Lactarius volemus, which demonstrated anticancer activity [183,184]. The chemical structures of steroids are shown in Figure 14, and the biological activity is shown in Table 5.

4.3.2. Steroid and Triterpenoid Hydroperoxides

A flowering herbaceous perennial plant from the family Araceae, Arum italicum, also known as Italian arum and Italian lords-and-ladies, contains a suite of hydroperoxysterols, including two (57 and 58) that are interesting for lipid metabolism [185]. Two steroids (59 and 60), which showed a cytotoxic effect against several human cancer cell lines, have been isolated from the bark of the chinaberry tree, Melia azedarach [186]. The chemical structures of steroids are shown in Figure 15, and the biological activity is shown in Table 6.
Ponce and co-workers obtained ergosterol 7-hydroperoxide (61) by the photo-oxidation of ergosterol with singlet oxygen in vivo and in vitro [187]. In addition, the yeast Saccharomyces cerevisiae with the singlet oxygen leads to rapid oxidation of ergosterol to ergosterol 7-hydroperoxide (61) [188].
A tree called Sakae Naa (Combretum quadrangulare) in Vietnam, Cambodia, Laos, Myanmar, and Thailand contained a cycloartane-type triterpene quadrangularic acid F (62), and the aqueous and EtOH extracts show antibacterial, anti-HIV, hepatoprotective, and cytotoxic activities [189,190,191].
The plant Proboscidea louisiana produced dammarane triterpenes known as probosciderol I (63) [192], and the stem bark of Rhus javanica contained isofouquierone peroxide (64) [193]. The leaves of Melaleuca ericifolia contained antiproliferative norlupane triterpene (65) [194], and the aerial roots of Ficus microcarpa afforded similar norlupane triterpene (66) [195].

4.3.3. Comparison of Biological Activities of Peroxy Steroids Derived from Natural Sources

According to published data, most natural peroxides isolated from both plants and marine invertebrates show predominantly antiprotozoal activity. Such compounds include diterpenoids, triterpenoids, and steroids [166,167,168,171,173,196,197,198,199].
Analysis of PASS data on peroxy steroids and triterpenoids such as endoperoxides and hydroperoxides showed that most of these lipids have a high confidence level of more than 90 percent, but nevertheless, only three of all peroxy steroids deserve attention; these are steroids numbered 59, 63, and 66, which have a confidence level of over 93 percent. Figure 16 presents the 3D graph showing the predicted and calculated biological activity of steroid hydroperoxides.

5. Carbon-Bridged Steroids (CBS) and Triterpenoids

In both natural and synthetic steroids, when an additional ring is formed within the steroid skeleton, through a direct bond between any two carbon atoms (or more) of the steroid ring system or an attached side chain, such steroids (or triterpenoids) are called carbon-bridged steroids [13,200,201,202].
Of the more than 500 carbon-bridged steroids and triterpenoids studied, we found only twelve lipids that have a confidence level of more than 90 percent as potential lipid regulators. We give their description and their sources in nature below [13,203].
Studying the photoproducts obtained by photochemical processes of vitamin D, the cyclobutane containing derivative 67 was identified [204], and similar secosteroid named toxisterol (68), as a minor transformation product of vitamin D2, has been found in various mushrooms [205]. The chemical structures of steroids and triterpenoids are shown in Figure 17, and the biological activity is shown in Table 7.
A unique steroid containing a 5,19-cycloergostane skeleton, (3β,5β,6β,7α,22E,24ς)-5,19-cycloergost-22-ene-3,6,7-triol, named hatomasterol (69), was found in the extracts of the Okinawan sponge Stylissa sp., and this compound demonstrated cytotoxicity against HeLa cells in vitro [206]. Steroidal saponins named poecillastrosides E (70) and G (71), an oxidized methyl at C-18, into a primary alcohol or a carboxylic acid, have been found in extracts of the Mediterranean deep-sea sponge Poecillastra compressa. Poecillastroside E bearing a carboxylic acid at C-18 showed antifungal activity against Aspergillus fumigatus [207], and other cyclopropyl containing steroids (72) and (75) were found in the methanol extract of the marine sponge Petrosia weinbergi [208]. Cycloart-24-en-3-ol (73) was detected in ethanol extract of marine green alga Cladophora fascicularis [209].
A cytotoxic sterol named petrosterol (74) showed cytotoxic activities on A549, HL-60, MCF-7, SK-OV-3, and U937 cancer cell lines, and was present in extracts of several marine sponges such as Vietnamese sponge Ianthella sp., Petrosia spheroïda from the Indian Ocean, Halichondria cf. panicea of the Japanese island Iriomote, and Japanese marine sponge Strongylophora corticate [210,211,212,213].
A rare steroid named calysterol (76), the minor sterol component of the sponge Calyx niceaensis and Petrosia ficiformis, possessing the unique feature of a cyclopropene ring bridging C23,24, and isocalysterol (77), was detected in the same sponge [214,215,216,217,218]. Sterol ester, 24,26-cyclo-5α-cholest-(22E)-en-3β-4′,8′12′-trimetyltridecanoate (78), has been isolated from a deep-water marine sponge, Xestospongia sp. [218].

Comparison of Biological Activities of CBS Steroids and Triterpenoids

Carbon-bridged steroids (CBS) and triterpenoids belong to a rare group of natural hormones found in various natural sources such as green, yellow-green, and red algae, sea sponges, soft corals, ascidians, starfish, and other marine invertebrates. In addition, this group of rare lipids is found in amoebas, fungi, fungal endophytes, and plants [13,203].
We have isolated carbon-bridged steroids presented in Figure 18, which, according to the PASS data, have a confidence level of more than 90 percent. Among this group of lipids, we identified three, numbered 70, 74, and 78, the activity of which most clearly reflects their regulatory functions of lipid metabolism, with antihypercholesterolemic properties dominating. In addition, these steroids can be used as inhibitors of cholesterol synthesis and as drugs for the treatment of atherosclerosis. The 3D graph demonstrating the predicted and calculated biological activity of carbon-bridged steroids is shown in Figure 18.

6. Neo Steroids Derived from Terrestrial and Marine Sources

Secondary metabolites containing a tertiary butyl group (or tertbutyl unit) are rather rare compounds found in cyanobacteria, plant leaves, fungi, marine invertebrates, and algae [12,219,220,221].
Neo steroids are a small group of lipids that are synthesized by yeast and fungi and are found in various parts of plants. In recent years, with the improvement of steroid analysis methods, they have been found in seaweeds, marine sponges (class Demospongiae), anemones (class Anthozoa), and cucumbers (class Holothuroidea) [12,219].
Two neo steroids (79 and 85) were present in leaves and stems and the pericarp of the fruit and roots of a plant from the family Cucurbitaceae [222], and another sterol, 24-methylene-25-methyl-lathosterol (80), was isolated from aerial parts of the herbaceous plant, Sicyos angulatus [223]. The chemical structures of steroids and triterpenoids are shown in Figure 19, and the biological activity is shown in Table 8.
Aerial parts of the strongly aromatic herb Ocimum basilicum from the Labiatae family, such as seeds, flowers, and roots, are widely used as medicines [224,225,226]. The leaves and flowers of this plant are used in folk medicine as a tonic and anthelmintic [227]. Leaf tea is used to treat flatulence and dysentery, while the plant’s oil may be useful for relieving mental fatigue, colds, cramps, rhinitis, and as a first aid for treating wasp stings and snake bites [227,228]. A species of this plant from Pakistan contains (22E)-24ξ-ethyl-25-methylcholesta-5,22-diene-3β-ol-3-O-D-gluco-pyranoside (81) [229].
Three neo steroids (82, 83 and 86) have been isolated from this auxotroph mutant Saccharomyces cerevisiae strain GL7 using appropriate substrates for biosynthesis [230]. The sterol C24-methyl transferase from Trypanosoma brucei TbSMT1 produces 24-methyl sterols that serve as substrates for 24-dimethyl sterols that contain a Δ25(27)-bond, and the neo steroid (84) was isolated from the extract S. cerevisiae [231]. Topsentinols C (87) and E (88) contain a tertiary butyl group in steroids, and these neo steroids were obtained from the Okinawan marine sponge Topsentia sp. [232,233]. (3β,24E)-25-Methylstigmasta-5,24(28)-dien-3-ol (89) and axinyssasterol (90) were identified from a marine sponge Pseudoaxinyssa sp. [234].
Neo steroid (3β,22E,24ξ)-28,28-dimethyl-stigmasta-5,22,25-trien-3-ol acetate (91) and (3β,22E)-25-methyl-stigmasta-5,22-dien-3-ol (92) were obtained from an ethanol extract of the sponge Halichondria sp. [235,236], and the compound (93) was also found in specimens of the sponge T. aplysinoides from the inshore waters of Sri Lanka [236]. The antimicrobial halistanol (93) was isolated from the Okinawan sponge Halichondria cf. moorei more than 25 years ago [237].
The Atlantic tropical sponge Erylus goffrilleri contains unusual lanostane glycosides, erylosides R (94) and T (95), and the same glycosides were isolated from the Caribbean sponge E. goffrilleri. Both eryloside glycosides R and T exhibit cytotoxic activities against Ehrlich carcinoma tumor cells [238,239].

Comparison of Biological Activities of Neo Steroids

Neo steroids are a rare group of naturally occurring lipid molecules that exhibit high levels and a wide range of activities. The chemical structures shown in Figure 19 have been found in plant and marine invertebrate extracts. According to PASS data, neo steroids show a high confidence level of up to 98.9 percent, with antihypercholesterolemic activity being dominant. In addition, virtually all neo steroids are cholesterol synthesis inhibitors and can be used to treat atherosclerosis and related diseases.
Of the seventeen neo steroids, we have selected four that show a high confidence level of 96.9 to 98.9 percent. Figure 20 demonstrates the 3D graph and shows the predicted and calculated biological activity of neo steroids (compound numbers: 81, 86, 89, and 93) showing the highest degree of confidence, more than 96.9%.

7. Miscellaneous Steroids and Triterpenoids Derived from Marine Sources

In this section, we have collected steroids that do not belong to the first six groups of triterpenoids but show high antihypercholesterolemic activity. Mostly, the steroids shown in Figure 20 are found in soft corals collected in various regions of the world’s oceans. An interesting question is why from coral? The fact is that, by studying the activities of various marine organisms, we concluded that corals or their fungal endophytes synthesize many biologically active metabolites. It is well known that corals are associated with many microscopic fungi, so a reasonable question arises: what synthesizes bioactive molecules in corals? Whether they do so themselves or their fungal endophytes or bacteria is a question that remains open [240,241,242].
Cytotoxic steroid called stereonsteroid G (96) was isolated from the methylene chloride extract of the Formosan soft coral Stereonephthya crystalliana. The extract of this coral showed significant cytotoxicity against A549, HT-29 and P-388 cancer cells in vitro [243]. The chemical structures of steroids and triterpenoids are shown in Figure 21, and the biological activity is shown in Table 9.
Trihydroxy sterol, pregna-5-ene-3,20,21-triol (97), has been isolated from the Gulf of California gorgonian Muricea cf. austera [244], and a rare spiroketal steroid, 22-acetoxy-3,25-dihydroxy-16,24,20–24-bisepoxy-(3,16,20S,22R,24S)-cholest-5-ene (98) was found in extracts of the Indian Ocean gorgonian, Gorgonella umbraculum [245]. The cholestane class steroidal hemiacetals named anastomosacetal A (99) was obtained from the gorgonian coral Euplexaura anastomosans, collected off the shore of Keomun Island, South Sea Korea [246], and petasitosterone B (100) was isolated from a Formosan marine soft coral Umbellulifera petasites [247]. Petasitosterone B (100) displayed inhibitory activity against the proliferation of a limited panel of cancer MOLT-4 and DLD-1 cell line. Steroidal glycoside (101) was isolated from water–methanol solutions of the soft coral Sinularia gibberosa [248], and steroid 102 was found in the methanol extract of the Vietnamese soft coral Sinularia nanolobata [249]. The minor sterol 103 was isolated from the soft coral extract of the genus Sinularia, and it was synthesized [250]. Steroid named crassarosteroside A (104) was obtained from Sinularia granosa and S. crassa soft coral extracts [251,252], compound 105 has been isolated from Sinularia conferta and S. nanolobata [253,254], and metabolite 106 was detected in MeOH extract of the soft coral S. cruciata [255]. Oxysterol (107) was detected in extracts of octocoral of the genus Gorgonia from the eastern Pacific, Panama [256].

Comparison of Biological Activities of Soft Coral Steroids

The chemical and structural diversity of soft corals sterols and triterpenoids is well known and has been documented in several review articles in the literature [128,130,257,258,259,260,261]. PASS analysis shows that the steroids in Figure 21 synthesized by soft corals are indeed of interest due to their high anticholesterol activity. Both the biological activities found using PASS and those obtained experimentally coincide. In addition, we have identified three steroids, numbered 99, 101, and 104, which demonstrate antihypercholesterolemic activity with a high degree of certainty. Figure 22 shows a 3D graph of predicted and calculated biological activity of these steroids.

8. Synthetic and Semi-Synthetic Steroids and Triterpenoids and Comparison of Their Biological Activities

Steroid hormones and triterpenoids belong to the group of physiologically active substances (sex hormones, corticosteroids, etc.) that regulate vital processes in vertebrates and many species of invertebrates and humans [262,263,264,265]. They are regulators of the fundamental vital processes of a multicellular organism-coordinated growth, differentiation, reproduction, adaptation, and behavior [266,267,268]. For more than 90 years, steroid hormones and triterpenoids have been the subject of close attention of chemists since synthetic analogues have long replaced natural steroids and triterpenoids [269,270,271,272,273]. It is known that semi-synthetic or synthetic steroid hormones have properties that steroids do not have, isolated from natural sources. In this section, we present synthetic and semi-synthetic steroids and triterpenoids that contain heteroatoms and do not exist in nature but demonstrate activities that are necessary for pharmacologists and physicians.

8.1. Bioactive Epithio Steroids and Triterpenoids

Anabolic steroids are pharmacological drugs that mimic the effect of the male sex hormone testosterone and its derivatives [274,275,276]. Anabolic steroids accelerate the synthesis of protein within cells, which leads to a pronounced hypertrophy of the muscle tissue, because of which, they have found wide application in sports medicine and bodybuilding [277,278,279].
Semi- and/or synthetic epithio steroids represent a rare group of bioactive lipids, since they are hydrophobic molecules insoluble in water, which are not found in nature. Epithio steroids have been reported to possess a variety of cytotoxic activities, and they are widely used as anticancer agents. The thiirane group is an important substance and shows some promising biological activities. Steroids containing an epithio group in positions 2 and 3 are anabolic steroids and are widely known and used in sports medicine. Representatives of this group of steroids are of great interest for pharmaceutical chemistry and medicine [280,281,282,283,284,285,286]. The most widely known are such epithio steroids that are used in sports pharmacology and medicine: epistane (108, 2α,3α-epithio-17α-methyl-5α-androstan-17β-ol), epitiostanol (109, 2α,3α-epithio-5α-androstan-17β-ol), a known potent antiestrogenic and antitumor agent, and hemapolin (110, 2β,3β-epithio-17α-methyl-5α-androstan-17β-ol) [282,283,287,288,289,290,291]. The chemical structures of epithio steroids are shown in Figure 23 and the biological activities are shown in Table 10. Presented in Figure 24, the anabolic 2α,3α-epithio chlostane (111) shown dominant anticancer activity, and steroid (112) demonstrated dominant properties as an antisecretory agent with 96.7% confidence and acts as an estrogen antagonist with 94.6% confidence.
Epithio steroids (113–115 and 117) and are cholesterol antagonists, and the anticancer triterpenoid (116), which was synthesized from a natural sample of 18β-glycyrrhetinic acid [292,293], shows lipid metabolism regulator properties.

8.2. Bioactive Selena Steroids

Selenium is an essential metalloid, and it is one of the most necessary trace elements for humans [296]. Selenium occupies an important place in the regulation of metabolism in humans, and therefore, it is necessary to monitor its presence in consumed foods [297,298]. The Allium and Brassica families as well as Brazil nuts, mushrooms (shiitake and white mushrooms), beans, chia seeds, brown rice, sunflower, sesame and flax seeds, and cabbage and spinach contain high enough selenium and organoselenium concentrations [299,300].
There are also many excellent reviews in the literature, which are devoted to the biological role and functions of organoselenium compounds [301,302,303,304]. Apparently, selena steroids are the main group of the essential metalloids that have been synthesized over the past 50 years, and approximately 300 have been synthesized [304,305,306,307,308,309].
The selena steroids numbered 118, 119, 124, 125, 126, and 127 show dominant antihypercholesterolemic activity with a low degree of confidence from 90.5 to 91.2%, although for steroid number 128, the confidence was 95.3%. For another group, the selena steroids numbered 120, 121, 122, and 123, the dominant properties are hyperlipemia, treatment of atherosclerosis, and treatment of lipoprotein disorders with a strong degree of confidence up to 99.6%. The chemical structures of steroids are shown in Figure 25, and the biological activity is shown in Table 11. Figure 26 shows the 3D graph the predicted and calculated biological activity of the selena steroids numbered 120, 121, and 122 with dominant properties as hyperlipemia and treatment of atherosclerosis.

8.3. Bioactive Tellura Steroids

Tellura steroids are a rare group of organic synthetic compounds whose biological activity is of great interest for medicine, pharmacology, and the pharmaceutical industry [304,306,308,309,311]. The chemical structures of steroids and triterpenoids are shown in Figure 27, and the biological activity is shown in Table 12.
We found only four tellura steroids, which exhibit properties as regulators of lipid metabolism, dominated by antihypercholesterolemic activity. However, the most interesting from the point of view of pharmacological values is tellura steroid with number 129. In addition to its antihypercholesterolemic activity, it is worth pointing out that this steroid has also been shown to be used as an agent for the treatment of neurodegenerative diseases Alzheimer’s and Parkinson’s with strong confidence, over 94 percent. The 3D graph demonstrating the predicted and calculated biological activity of the tellura steroid (129) is shown in Figure 28.

8.4. Bioactive Astatosteroids

Astatine is natural radioelement that has short-lived isotopes, and synthetic organic astatine compounds are commonly used for radiotherapy [312,313,314]. Steroids containing astatine, which are called astatosteroids, were first synthesized approximately 40 years ago [315]. Some astatosteroids (2- and 4-astatoestradiol and 6-At-cholesterol, 135, 136, and 137) have been synthesized in high radiochemical yields by the reaction of 211At/I2 and the corresponding chloromercury compounds. The stability in vitro was determined under different conditions in comparison with the analogous iodo compounds [313]. More recently, 6-astatomethyl-19-norcholest-5(10)-en-3β-ol (134) was synthesized at a yield of 60–70% [316]. The biological activity of these compounds has not been determined. The predicted biological activity of astatosteroids is presented in Table 13. The most characteristic biological properties for these steroids were antineoplastic, antiseborrheic, antisecretoric, and antihypercholesterolemic activities. The chemical structures of steroids are shown in Figure 29 and the biological activity is shown in Table 13. For all astatosteroids shown in Figure 29, antihypercholesterolemic activity is dominated. In addition, all steroids of this group, as shown by PASS, have properties as a treatment for bone diseases. This is a rare property for steroids. Figure 30 shows the 3D graph the predicted and calculated biological activity of the astatosteroid (133).

9. Conclusions

This review focuses on the intriguing topic of lipid metabolism regulation. The literature does not fully describe the means that regulate lipid metabolism. Steroids and triterpenoids presented in this review are of great interest for medicine, and some of them may be potential regulators of lipid metabolism. However, experimental work is required to confirm this thesis. In the world in general, and in North America in particular, the study of biological activities using computer programs is gaining popularity. This is due to the fact that the number of isolated natural and synthetic compounds has long exceeded 20 million; there is no technical possibility of determining biological activity experimentally. Using the PASS program for the last fifteen years has shown that we are on the right track. During this time, we have investigated over 10,000 compounds and identified their potential biological activities. Based on early studies, we have selected a group of steroids and triterpenoids that are presented in this review and correspond to the name of the topic, as potential regulators of lipid metabolism.

Funding

This work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Acknowledgments

The author is grateful to Anne Kathrin Bendt (Life Sciences Institute, National University of Singapore, Singapore) who initiated this review, and grateful to Tatyana A. Gloriozova (Institute of Biomedical Chemistry, Moscow, Russia) for prompt help in determining the biological activity of the steroids and triterpenoids presented in the article.

Conflicts of Interest

The author declares that he has no known competing financial interests or personal relationships that could affect the work described in this article.

References

  1. Cheng, X.; Smith, J.C. Biological membrane organization and cellular signaling. Chem. Rev. 2019, 119, 5849–5880. [Google Scholar] [CrossRef]
  2. Jensen, M.Ø.; Mouritsen, O.G. Lipids do influence protein function—The hydrophobic matching hypothesis revisited. Biochim. Biophys. Acta Biomembr. 2004, 1666, 205–226. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. MacCallum, J.L.; Tieleman, D.P. Hydrophobicity scales: A thermodynamic looking glass into lipid–protein interactions. Trends Biochem. Sci. 2011, 36, 653–662. [Google Scholar] [CrossRef] [PubMed]
  4. Lundstedt, E.; Kahne, D.; Ruiz, N. Assembly, and maintenance of lipids at the bacterial outer membrane. Chem. Rev. 2021, 121, 5098–5123. [Google Scholar] [CrossRef] [PubMed]
  5. Suzumura, M. Phospholipids in marine environments: A review. Talanta 2005, 66, 422–434. [Google Scholar] [CrossRef]
  6. Li, J.; Wang, X.; Zhang, T.; Wang, C.; Huang, Z.; Luo, X.; Deng, Y. A review on phospholipids and their main applications in drug delivery systems. Asian J. Pharm. Sci. 2015, 10, 81–98. [Google Scholar] [CrossRef]
  7. Dowhan, W. Molecular basis for membrane phospholipid diversity: Why are there so many lipids? Ann. Rev. Biochem. 1997, 66, 199–232. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  8. Berne, B.J.; Weeks, J.D.; Zhou, R. Dewetting and hydrophobic interaction in physical and biological systems. Ann. Rev. Phys. Chem. 2009, 60, 85–103. [Google Scholar] [CrossRef] [Green Version]
  9. Gisterå, A.; Hansson, G. The immunology of atherosclerosis. Nat. Rev. Nephrol. 2017, 13, 368–380. [Google Scholar] [CrossRef]
  10. Alexopoulos, N.; Raggi, P. Calcification in atherosclerosis. Nat. Rev. Cardiol. 2009, 6, 681–688. [Google Scholar] [CrossRef]
  11. Faulds, M.H.; Zhao, C.; Dahlman-Wright, K.; Gustafsson, J.Å. The diversity of sex steroid action: Regulation of metabolism by estrogen signaling. J. Endocrinol. 2011, 212, 3–12. [Google Scholar] [CrossRef]
  12. Dembitsky, V.M. Antitumor and hepatoprotective activity of natural and synthetic neo steroids. Prog. Lipid Res. 2020, 79, 101048. [Google Scholar] [CrossRef]
  13. Dembitsky, V.M.; Gloriozova, T.A.; Poroikov, V.V. Antitumor profile of carbon-bridged steroids (CBS) and triterpenoids. Mar. Drugs 2021, 19, 324. [Google Scholar] [CrossRef]
  14. Pounina, T.A.; Gloriozova, T.A.; Savidov, N.; Dembitsky, V.M. Sulfated and sulfur-containing steroids and their pharmacological profile. Mar. Drugs 2021, 19, 240. [Google Scholar] [CrossRef]
  15. Zagoskin, P.P.; Erlykina, E.I. Bile acids as a new type of steroid hormones regulating nonspecific energy expenditure of the body (review). Sovremen. Tehnol. Med. 2020, 12, 114. [Google Scholar] [CrossRef]
  16. Ko, C.W.; Qu, J.; Black, D.D.; Tso, P. Regulation of intestinal lipid metabolism: Current concepts and relevance to disease. Nat. Rev. Gastroenterol. Hepatol. 2020, 17, 169–183. [Google Scholar] [CrossRef]
  17. De Bose-Boyd, R.A. Significance, and regulation of lipid metabolism. Semin. Cell Dev. Biol. 2018, 81, 97. [Google Scholar] [CrossRef]
  18. Luo, J.; Yang, H.; Song, B.L. Mechanisms, and regulation of cholesterol homeostasis. Nat. Rev. Mol. Cell Biol. 2020, 21, 225–245. [Google Scholar] [CrossRef]
  19. Schoeler, M.; Caesar, R. Dietary lipids, gut microbiota, and lipid metabolism. Rev. Endocr. Metab. Disord. 2019, 20, 461–472. [Google Scholar] [CrossRef] [Green Version]
  20. Matsushita, Y.; Nakagawa, H.; Koike, K. Lipid metabolism in oncology: Why it matters, how to research, and How to treat. Cancers 2021, 13, 474. [Google Scholar] [CrossRef]
  21. Edgar, A.; Doisy, E.A. An ovarian hormone: Preliminary report on its localization, extraction and partial purification, and action in test animals. J. Am. Med. Assoc. 1923, 81, 819–821. [Google Scholar]
  22. Doisy, E.A.; Clement, D.V.; Sidney, T. Folliculin from urine of pregnant women. Am. J. Phys. 1929, 90, 329–330. [Google Scholar]
  23. Butenandt, A.B. Über, Progynonein krystallisiertes weibliches Sexualhormon. Die Naturwissenschaften 1929, 17, 879. [Google Scholar] [CrossRef]
  24. Butenandt, A. Über physikalische und chemische Eigenschaften des krystallisierten Follikelhormons. Untersuchungen über das weibliche Sexualhormon. Hoppe-Seyler’s Zeit. Physiol. Chem. 1930, 191, 140–156. [Google Scholar] [CrossRef]
  25. Butenandt, A. Über die chemische Untersuchung der Sexualhormone. Zeit Angew. Chem. 1931, 44, 905–908. [Google Scholar] [CrossRef]
  26. Butenandt, A.; Jacobi, H. Über die Darstellung eines krystallisierten pflanzlichen Tokokinins (Thelykinins) und seine Identifizierung mit dem α-Follikelhormon. Untersuchungen über das weibliche Sexualhormon. Hoppe Seyler’s Z. Physiol. Chem. 1933, 218, 104–112. [Google Scholar] [CrossRef]
  27. Ramirez, M.P.; Haas, S. Hormone replacement therapy for women: The benefits, risks, and considerations for use in 2003. Curr. Opinion Endocrin. Diabet. 2003, 10, 400–418. [Google Scholar] [CrossRef]
  28. Fluhmann, C.F. Estrogenic hormones: Their clinical usage. Cal. West Med. 1938, 49, 362–366. [Google Scholar]
  29. Younglai, E.V.; Solomon, S. Formation of estra-1,3,5(10)-triene-3,15a,16a,17b-tetrol (estetrol) and estra-1,3,5(10)-triene-3,15a,17btriol from neutral precursors. J. Clin. Endocrinol. Metab. 1968, 28, 1611–1617. [Google Scholar] [CrossRef]
  30. Raeside, J.I. A brief account of the discovery of the fetal/placental unit for estrogen production in equine and human pregnancies: Relation to human medicine. Yale J. Biol. Med. 2017, 90, 449–461. [Google Scholar]
  31. Trifunović, J.; Borčić, V.; Vukmirović, S.; Mikov, M. Structural insights into anticancer activity of D-ring modified estrone derivatives using their lipophilicity in estimation of SAR and molecular docking studies. Drug Test Anal. 2017, 9, 1650. [Google Scholar] [CrossRef] [Green Version]
  32. Dohrn, M.; Faure, W.; Poll, H.; Blotevogel, W. Tokokinine, Stoff mit sexualhormonartiger Wirkung aus Pflanzenzellen. Med. Klin. 1926, 22, 1417–1419. [Google Scholar]
  33. Skarzynski, B. An oestrogenic substance from plant material. Nature 1933, 131, 766. [Google Scholar]
  34. Janeczko, A.; Skoczowski, A. Mammalian sex hormones in plants. Folia Histochem. Cytobiol. 2005, 43, 71–79. [Google Scholar]
  35. Jailer, J.W. The metabolism of the estrogens: A review. J. Clin. Endocrinol. 1949, 9, 557–572. [Google Scholar] [CrossRef]
  36. Xu, Y.; López, M. Central regulation of energy metabolism by estrogens. Mol. Metabol. 2018, 15, 104–115. [Google Scholar] [CrossRef]
  37. Ventura-Clapier, R.; Piquereau, J.; Veksler, V.; Garnier, A. Estrogens, estrogen receptors effects on cardiac and skeletal muscle mitochondria. Front. Endocrinol. 2019, 10, 557. [Google Scholar] [CrossRef] [Green Version]
  38. Le, J.; Thomas, N.; Gurvich, C. Cognition, the menstrual cycle, and premenstrual disorders: A Review. Brain Sci. 2020, 10, 198. [Google Scholar] [CrossRef] [Green Version]
  39. Su, Z.; Yuan, W.; Wang, P.; Li, S. Ethnobotany, phytochemistry, and biological activities of Taxodium Rich. Pharm. Crops 2013, 4, 1–14. [Google Scholar]
  40. Sukandar, E.Y.; Suganda, A.G.; Pertiwi, G.U. Aktivitas sediaan yang mengandung ekstrak daun ketapang pada kulit kelinci yang diinfeksi dengan ephidermophyton floccosum dan Candida albicans. Acta Pharm. Ind. 2007, 32, 45–49. [Google Scholar]
  41. Suganda, A.G.; Sukandar, E.Y.; Hardhiko, R.S. Aktivitas antimikroba ekstrak etanol daun yang dipetik dan ekstrak air daun gugur pohon ketapang (Terminalia catappa L.). Acta Pharm. Ind. 2004, 29, 129–133. [Google Scholar]
  42. Suganda, A.G.; Sukandar, E.Y.; Ratna, L. Aktivitas antimikroba ekstrak etanol daun dua belas jenis Tumbuhan marga terminalia (Combretaceae). Acta Pharm. Ind. 2006, 31, 18–23. [Google Scholar]
  43. Pranjali, C.; Lokesh, R. A review on medicinal potential of Terminalia catappa. Int. J. Green Pharm. 2020, 14, 229–234. [Google Scholar]
  44. Misico, R.I.; Veleiro, A.S.; Burton, G.; Oberti, J.C. Withanolides from Jaborosa leucotricha. Phytochemistry 1997, 45, 1045–1048. [Google Scholar] [CrossRef]
  45. Yan, X.-H.; Liu, H.-L.; Huang, H.; Li, X.-B.; Guo, Y.-W. Steroids with aromatic A rings from the Hainan soft coral Dendronephthya studeri Ridley. J. Nat. Prod. 2011, 74, 175–180. [Google Scholar] [CrossRef]
  46. Lu, Z.; Van Wagoner, R.M.; Harper, M.K.; Hooper, J.N.A.; Ireland, C.M. Two ring-A aromatized bile acids from the marine sponge Sollasella moretonensis. Nat. Prod. Commun. 2010, 5, 1571–1574. [Google Scholar] [CrossRef] [Green Version]
  47. Yeung, B.K.S.; Hamann, M.T.; Scheuer, P.J.; Kelly-Borges, M. Hapaioside: A 19-norpregnane glycoside from the sponge Cribrochalina olemda. Tetrahedron 1994, 50, 12593–12598. [Google Scholar] [CrossRef]
  48. Nakao, Y.; Kuo, J.; Yoshida, W.Y.; Kelly, M.; Scheuer, P.J. More kapakahines from the marine sponge Cribrochalina olemda. Org. Lett. 2003, 5, 1387–1390. [Google Scholar] [CrossRef]
  49. Tomono, Y.; Hirota, H.; Imahara, Y.; Fusetani, N. Four new steroids from two octocorals. J. Nat. Prod. 1999, 62, 1538–1541. [Google Scholar] [CrossRef] [PubMed]
  50. Barrero, A.F.; Oltra, J.E.; Poyatos, J.A.; Jiménez, D.; Oliver, E. Phycomysterols and other sterols from the fungus Phycomyces blakesleeanus. J. Nat. Prod. 1998, 61, 1491–1496. [Google Scholar] [CrossRef] [Green Version]
  51. Liu, X.H.; Tang, X.Z.; Miao, F.P.; Ji, N.Y. A new pyrrolidine derivative and steroids from an algicolous Gibberella zeae strain. Nat. Prod. Commun. 2011, 6, 1243–1246. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Luo, X.; Li, F.; Shinde, P.B.; Hong, J.; Lee, C.-O.; Im, K.S.; Jung, J.H. 26,27-Cyclosterols and other polyoxygenated sterols from marine sponge Topsentia sp. J. Nat. Prod. 2006, 69, 1760–1768. [Google Scholar] [CrossRef] [PubMed]
  53. Brown, A.C.; Fraser, T.R. The connection of chemical constitution and physiological action. Trans. Roy. Soc. Edinb. 1868, 25, 224–242. [Google Scholar]
  54. Cros, A.F.A. Action de L’alcohol Amylique Sur L’organisme. Ph.D. Thesis, University of Strasbourg, Strasbourg, France, 1863. [Google Scholar]
  55. Richet, M.C. Note sur le rapport entre la toxicité et les propriétes physiques des corps. Compt. Rend. Soc. Biol. 1893, 45, 775–776. [Google Scholar]
  56. Meyer, H. Zur Theorie der AIkoholnarkose. Arch. Exp. Path. Pharm. 1899, 42, 109–118. [Google Scholar] [CrossRef]
  57. Overton, C.E. Studien über Die Narkose; Fischer: Jena, Germany, 1901. [Google Scholar]
  58. Hammett, L.P. Some relations between reaction rates and equilibrium constants. Chem. Rev. 1935, 17, 125–136. [Google Scholar] [CrossRef]
  59. Hammett, L.P. The effect of structure upon the reactions of organic compounds. Benzene derivatives. J. Am. Chem. Soc. 1937, 59, 96–103. [Google Scholar] [CrossRef]
  60. Taft, R.W. Separation of polar, steric and resonance effects in reactivity. In Steric Effects in Organic Chemistry; Newman, M.S., Ed.; Wiley: Hoboken, NJ, USA, 1956; pp. 556–675. [Google Scholar]
  61. Hansch, C.; Fujita, T. π-τ-π Analysis. A method for the correlation of biological activity and chemical structure. J. Am. Chem. Soc. 1964, 86, 1616–1626. [Google Scholar] [CrossRef]
  62. Hansch, C.; Leo, A. Exploring QSAR; American Chemical Society: Washington, DC, USA, 1995. [Google Scholar]
  63. Sliwoski, G.; Kothiwale, S.; Meiler, J.; Lowe, E.W., Jr. Computational methods in drug discovery. Pharm. Rev. 2014, 66, 334–395. [Google Scholar] [CrossRef] [Green Version]
  64. Leelananda, S.P.; Lindert, S. Computational methods in drug discovery. Beilstein J. Org. Chem. 2016, 12, 2694–2718. [Google Scholar] [CrossRef] [Green Version]
  65. Kokh, D.B.; Amaral, M.; Bomke, J.; Grädler, U.; Musil, D. Estimation of drug-target residence times by τ-random acceleration molecular dynamics simulations. J. Chem. Theor. Comput. 2018, 14, 3859–3869. [Google Scholar] [CrossRef]
  66. Cherkasov, A.M.; Muratov, E.N.; Fourches, D.; Varnek, A.; Baskin, I.I. QSAR modeling: Where have you been? Where are you going to? J. Med. Chem. 2014, 57, 4977–5010. [Google Scholar] [CrossRef] [Green Version]
  67. Burov, Y.V.; Poroikov, V.V.; Korolchenko, L.V. National system for registration and biological testing of chemical compounds: Facilities for new drugs search. Bull. Natl. Cent. Biol. Act. Comp. 1990, 1, 4–25. [Google Scholar]
  68. Muratov, E.N.; Bajorath, J.; Sheridan, R.P.; Tetko, I.; Filimonov, D.; Poroikov, V.; Oprea, T. QSAR without borders. Chem. Soc. Rev. 2020, 49, 3525–3564. [Google Scholar] [CrossRef]
  69. Poroikov, V.V.; Filimonov, D.A.; Gloriozova, T.A.; Lagunin, A.A.; Druzhilovskiy, D.S.; Rudik, A.V. Computer-aided prediction of biological activity spectra for organic compounds: The possibilities and limitations. Russ. Chem. Bull. 2019, 68, 2143–2154. [Google Scholar] [CrossRef]
  70. Filimonov, D.A.; Druzhilovskiy, D.S.; Lagunin, A.A.; Gloriozova, T.A.; Rudik, A.V.; Dmitriev, P.V.; Poroikov, V.V. Computer-aided prediction of biological activity spectra for chemical compounds: Opportunities and limitations. Biom. Chem. Res. Method. 2018, 1, e00004. [Google Scholar] [CrossRef] [Green Version]
  71. Anusevicius, K.; Mickevicius, V.; Stasevych, M.; Zvarych, V.; Komarovska-Porokhnyavets, O.; Novikov, V.; Tarasova, O.; Gloriozova, T.; Poroikov, V. Design, synthesis, in vitro antimicrobial activity evaluation and computational studies of new N-(4-iodophenyl)-Alanine derivatives. Res. Chem. Intermed. 2015, 41, 7517–7540. [Google Scholar] [CrossRef]
  72. Murtazalieva, K.A.; Druzhilovskiy, D.S.; Goel, R.K.; Sastry, G.N.; Poroikov, V.V. How good are publicly available web services that predict bioactivity profiles for drug repurposing? SAR QSAR Environ. Res. 2017, 28, 843–862. [Google Scholar] [CrossRef]
  73. PASS Online. Available online: http://www.way2drug.com/passonline/ (accessed on 4 June 2021).
  74. Lagunin, A.A.; Goel, R.K.; Gawande, D.Y.; Priynka, P.; Gloriozova, T.A.; Dmitriev, A.V.; Ivanov, S.M.; Rudik, A.V.; Konova, V.I.; Pogodin, P.V. Chemo- and bioinformatics resources for in silico drug discovery from medicinal plants beyond their traditional use: A critical review. Nat. Prod. Rep. 2014, 31, 1585–1611. [Google Scholar] [CrossRef]
  75. Goel, R.K.; Poroikov, V.; Gawande, D.; Lagunin, A.; Randhawa, P.; Mishra, A. Revealing medicinal plants useful for comprehensive management of epilepsy and associated co-morbidities through in silico mining of their phytochemical diversity. Planta Med. 2015, 81, 495–506. [Google Scholar]
  76. Dembitsky, V.M.; Gloriozova, T.A.; Poroikov, V.V. Naturally occurring plant isoquinoline N-oxide alkaloids: Their pharmacological and SAR activities. Phytomedicine 2015, 22, 183–202. [Google Scholar] [CrossRef] [PubMed]
  77. Gawande, D.Y.; Druzhilovsky, D.; Gupta, R.C.; Poroikov, V.; Goel, R.K. Anticonvulsant activity and acute neurotoxic profile of Achyranthes aspera Linn. J. Ethnopharmacol. 2017, 202, 97–102. [Google Scholar] [CrossRef] [PubMed]
  78. Dembitsky, V.M.; Dzhemileva, L.; Gloriozova, T.; D’yakonov, V. Natural and synthetic drugs used for the treatment of the dementia. Biochem. Biophys. Res. Commun. 2020, 524, 772–783. [Google Scholar] [CrossRef] [PubMed]
  79. Lagunin, A.; Povydysh, M.; Ivkin, D.; Luzhanin, V.; Krasnova, M. Antihypoxic action of Panax japonicus, Tribulus terrestris and Dioscorea deltoidea cell cultures: In silico and animal studies. Mol. Inform. 2020, 39, 2000093. [Google Scholar] [CrossRef]
  80. Dembitsky, V.M.; Ermolenko, E.; Savidov, N.; Gloriozova, T.A.; Poroikov, V.V. Antiprotozoal and antitumor activity of natural polycyclic endoperoxides: Origin, structures, and biological activity. Molecules 2021, 19, 686. [Google Scholar] [CrossRef]
  81. Qureshi, R.; Picon-Ruiz, M.; Aurrekoetxea-Rodriguez, I.; Kesmodel, S.; del Mar Vivanco, M.; Slinger, J.M. The major pre- and postmenopausal estrogens play opposing roles in obesity-driven mammary inflammation and breast cancer development. Cell Metab. 2020, 31, 1154–1172. [Google Scholar] [CrossRef]
  82. Ahmed, S.; Owen, C.P.; James, K.; Sampson, L.; Patel, C.K. Review of estrone sulfatase and its inhibitors—An important new target against hormone dependent breast cancer. Curr. Med. Chem. 2002, 9, 263–273. [Google Scholar] [CrossRef]
  83. Neilson, H.K.; Friedenreich, C.M.; Brockton, N.T.; Millikan, R.C. Physical activity and postmenopausal breast cancer: Proposed biologic mechanisms and areas for future research. Cancer Epidemiol. Biomark. Prev. 2009, 18, 11–27. [Google Scholar] [CrossRef] [Green Version]
  84. Bassol, S.; Garza-Flores, J. Review of ovulation return upon discontinuation of once-a-month injectable contraceptives. Contraception 1994, 49, 441–453. [Google Scholar] [CrossRef]
  85. McCarthy, M.M. Estradiol, and the developing brain. Physiol. Rev. 2008, 88, 91–134. [Google Scholar] [CrossRef] [Green Version]
  86. Soltysik, K.; Czekaj, P. Membrane estrogen receptors—Is it an alternative way of estrogen action? J. Physiol. Pharmacol. 2013, 64, 129–142. [Google Scholar]
  87. Mauvais-Jarvis, F.; Klein, S.L.; Levin, E.R. Estradiol, progesterone, immunomodulation, and COVID-19 outcomes. Endocrinology 2020, 161, 127. [Google Scholar] [CrossRef]
  88. Lappano, R.; Rosano, C.; De Marco, P.; De Francesco, E.M.; Pezzi, V.; Maggiolini, M. Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells. Mol. Cell. Endocrinol. 2010, 320, 162–170. [Google Scholar] [CrossRef]
  89. Ali, E.S.; Mangold, C.; Peiris, A.N. Estriol: Emerging clinical benefits. Menopause 2017, 24, 1081–1085. [Google Scholar] [CrossRef]
  90. Li, M.; Scott, R.Y. A review on structural elucidation of metabolites of environmental steroid hormones via liquid chromatography–mass spectrometry. Trends Anal. Chem. 2018, 109, 142–153. [Google Scholar]
  91. Brandán, S.A. Structural and vibrational studies of equilenin, equilin and estrone steroids. Biointerface Res. Appl. Chem. 2019, 9, 4502–4516. [Google Scholar]
  92. Bhavnani, B.R.; Stanczyk, F.Z. Pharmacology of conjugated equine estrogens: Efficacy, safety and mechanism of action. J. Steroid Biochem. Mol. Biol. 2014, 142, 16–29. [Google Scholar] [CrossRef]
  93. Ruder, H.J.; Loriaux, L.; Lipsett, M.B. Lipsett, Estrone sulfate: Production rate and metabolism in man. J. Clin. Investig. 1972, 51, 1020–1033. [Google Scholar] [CrossRef] [Green Version]
  94. Banjare, L.; Jain, A.K.; Thareja, A. Dual aromatase-sulphatase inhibitors (DASIs) for the treatment of hormone dependent breast cancer. Mini Rev. Med. Chem. 2021, 21, 10. [Google Scholar] [CrossRef]
  95. Blackwell, L.F.; Cooke, D.G.; Brown, S. The use of estrone-3-glucuronide and pregnanediol-3-glucuronide excretion rates to navigate the continuum of ovarian activity. Front. Public Health 2018, 6, 153. [Google Scholar] [CrossRef]
  96. Katayama, S.; Fishman, J. 2-Hydroxyestrone suppresses and 2-methoxyestrone augments the preovulatory prolactin surge in the cycling rat. Endocrinology 1982, 110, 1448–1450. [Google Scholar] [CrossRef]
  97. Gupta, M.; McDougal, A.; Safe, S. Estrogenic and antiestrogenic activities of 16α- and 2-hydroxy metabolites of 17β-estradiol in MCF-7 and T47D human breast cancer cells. J. Steroid Biochem. Mol. Biol. 1998, 67, 413–419. [Google Scholar] [CrossRef]
  98. Bradlow, H.L.; Telang, N.T.; Sepkovic, D.W.; Osborne, M.P. 2-Hydroxyestrone: The good estrogen. J. Endocrinol. 1996, 150, S259–S265. [Google Scholar]
  99. Williams, J.G.; Longcope, C.; Williams, K.I.H. 4-Hydroxyestrone: A new metabolite of estradiol-17β from humans. Steroids 1974, 24, 687–701. [Google Scholar] [CrossRef]
  100. Emons, G.; Hoppen, H.O.; Ball, P.; Knuppen, R. 4-Hydroxyestrone, isolation and identification in human urine. Steroids 1980, 36, 73–79. [Google Scholar] [CrossRef]
  101. Choi, H.J.; Lee, A.J.; Kang, K.S. 4-Hydroxyestrone, an endogenous estrogen metabolite. Can strongly protect neuronal cells against oxidative damage. Sci. Rep. 2020, 10, 7283. [Google Scholar] [CrossRef]
  102. Mueck, A.O.; Seeger, H.; Lippert, T.H. Estradiol metabolism and malignant disease. Maturitas 2002, 43, 1–10. [Google Scholar] [CrossRef]
  103. Anh, N.H.; Long, N.P.; Kim, S.J.; Min, J.E. Steroidomics for the prevention, assessment, and management of cancers: A systematic review and functional analysis. Metabolites 2019, 9, 199. [Google Scholar] [CrossRef] [Green Version]
  104. Seeger, H.; Deuringer, F.-U.; Wallwiener, D.; Mueck, A.O. Breast cancer risk during HRT: Influence of estradiol metabolites on breast cancer and endothelial cell proliferation. Maturitas 2004, 49, 235–240. [Google Scholar] [CrossRef]
  105. Fuhrman, B.J.; Schairer, C.; Gail, M.H.; Boyd-Morin, J. Estrogen metabolism and risk of breast cancer in postmenopausal women. J. Nat. Cancer Inst. 2012, 104, 326–339. [Google Scholar] [CrossRef]
  106. Fishman, J.; Cox, R.I.; Gallagher, T.F. 2-Hydroxyestrone: A new metabolite of estradiol in man. Archiv. Biochem. Biophys. 1960, 90, 318–319. [Google Scholar] [CrossRef]
  107. Taylor, H.C. The present status of gynecologic endocrine therapy. Bull. N. Y. Acad. Med. 1938, 14, 608–634. [Google Scholar] [PubMed]
  108. Marrian, G.F. The conjugated estrogens. Cold Spring Harb. Symp. Quant. Biol. 1937, 5, 16–24. [Google Scholar] [CrossRef]
  109. Dembitsky, V.M.; Savidov, N.; Poroikov, V.V.; Gloriozova, T.A.; Imbs, A.B. Naturally occurring aromatic steroids and their biological activities. Appl. Microbiol. Biotechnol. 2018, 102, 4663–4674. [Google Scholar] [CrossRef]
  110. De Riccardis, F.; Minale, L.; Riccio, R.; Giovannitti, B.; Iorizzi, M.; Debitus, C. Phosphated and sulfated marine polyhydroxylated steroids fromthe starfish Tremaster novaecaledoniae. Gazz. Chim. Ital. 1993, 123, 79–86. [Google Scholar]
  111. Dembitsky, V.M.; Gloriozova, T.A.; Savidov, N. Steroid phosphate esters and phosphonosteroids and their biological activities. Appl. Microbiol. Biotechnol. 2018, 102, 7679–7692. [Google Scholar] [CrossRef]
  112. Delrio, G.; Botte, V. Testosterone 17-phosphate and 19-nortestosterone 17-phosphate as substrate for rabbit prostate phosphatases. Biochim. Biophys. Acta 1970, 218, 327–332. [Google Scholar] [CrossRef]
  113. Kokado, A.; Tsuji, A.; Maeda, M. Chemiluminescence assay of alkaline phosphatase using cortisol-21-phosphate as substrate and its application to enzyme immunoassays. Anal. Chim. Acta 1997, 337, 335–340. [Google Scholar] [CrossRef]
  114. Ellam, T.J.; Chico, T.J. Phosphate: The new cholesterol? The role of the phosphate axis in non-uremic vascular disease. Atherosclerosis 2012, 220, 310–318. [Google Scholar] [CrossRef]
  115. Davis, S.C.; Szoka, F.C., Jr. Cholesterol phosphate derivatives: Synthesis and incorporation into a phosphatase and calcium-sensitive triggered release liposome. Bioconjug. Chem. 1998, 9, 783–792. [Google Scholar] [CrossRef]
  116. Sachs-Barrable, K.; Darlington, J.W.; Wasan, K.M. The effect of two novel cholesterol-lowering agents, disodium ascorbyl phytostanol phosphate and nanostructured aluminosilicate on the expression and activity of P-glycoprotein within Caco-2 cells. Lipids Health Dis. 2014, 13, 153–163. [Google Scholar] [CrossRef] [Green Version]
  117. Kutney, J.P.; Pritchard, H.P.; Lukic, T. Novel Compounds and Compositions Comprising Sterols and/or Stanols and Cholesterol Biosynthesis Inhibitors and Use Thereof in Treating or Preventing a Variety of Diseases and Conditions. Europe Patent EP1644399A2, 7 September 2003. [Google Scholar]
  118. Gunnarsson, P.O.; Norlén, B.J. Clinical pharmacology of polyestradiol phosphate. Prostate 1988, 13, 299–304. [Google Scholar] [CrossRef]
  119. Vil, V.; Gloriozova, T.A.; Terentev, A.O.; Zhukova, N.V.; Dembitsky, V.M. Highly oxygenated isoprenoid lipids derived from terrestrial and aquatic sources: Origin, structures, and biological activities. Vietnam J. Chem. 2019, 57, 1–15. [Google Scholar] [CrossRef]
  120. Vil, V.A.; Terentev, A.O.; Savidov, N.; Gloriozova, T.A.; Poroikov, V.V.; Pounina, T.A.; Dembitsky, V.M. Hydroperoxy steroids and triterpenoids derived from plant and fungi: Origin, structures and biological activities. J. Steroid Biochem. Mol. Biol. 2019, 190, 76–87. [Google Scholar] [CrossRef]
  121. Savidov, N.; Gloriozova, T.A.; Poroikov, V.V.; Dembitsky, V.M. Highly oxygenated isoprenoid lipids derived from fungi and fungal endophytes: Origin and biological activities. Steroids 2018, 140, 114–124. [Google Scholar] [CrossRef]
  122. Vil, V.A.; Gloriozova, T.A.; Terentev, A.O.; Savidov, N.; Dembitsky, V.M. Hydroperoxides derived from marine sources: Origin and biological activities. Appl. Microbiol. Biotechnol. 2019, 103, 1627–1642. [Google Scholar] [CrossRef]
  123. Dembitsky, V.M.; Gloriozova, T.A.; Poroikov, V.V. Naturally occurring marine α,β-epoxy steroids: Origin and biological activities. Vietnam J. Chem. 2018, 56, 409–433. [Google Scholar] [CrossRef]
  124. Rashidi, B.; Hoseini, Z.; Sahebkar, A.; Mirzaei, H. Anti-atherosclerotic effects of vitamins D and E in suppression of atherogenesis. J. Cell. Physiol. 2017, 232, 2968–2976. [Google Scholar] [CrossRef]
  125. Kutner, A.; Brown, G. Vitamins D: Relationship between structure and biological activity. Int. J. Mol. Sci. 2018, 19, 2119. [Google Scholar] [CrossRef] [Green Version]
  126. Dusso, A.S.; Brown, A.J.; Slatopolsky, E. Vitamin D. Am. J. Physiol. Renal. Physiol. 2005, 289, F8–F28. [Google Scholar] [CrossRef]
  127. Perez-Lopez, F.R. Vitamin D: The secosteroid hormone and human reproduction. Gynecolog. Endocrinol. 2007, 23, 13–24. [Google Scholar] [CrossRef] [PubMed]
  128. Ermolenko, E.V.; Imbs, A.B.; Gloriozova, T.A.; Poroikov, V.V.; Sikorskaya, T.V.; Dembitsky, V.M. Chemical diversity of soft coral steroids and their pharmacological activities. Mar. Drugs 2020, 20, 613. [Google Scholar] [CrossRef] [PubMed]
  129. Grishko, V.V.; Galaiko, N.V. Structural diversity, natural sources and pharmacological potential of naturally occurring A-seco-triterpenoids studies. Nat. Prod. Chem. 2016, 51, 51–149. [Google Scholar]
  130. Sica, D.; Musumeci, D. Secosteroids of marine origin. Steroids 2004, 69, 743–756. [Google Scholar] [CrossRef] [PubMed]
  131. Wu, S.H.; Luo, X.D.; Ma, Y.B.; Liu, Y.K.; Wu, D.G.; Zhao, B.; Lu, Y.; Zheng, Q.T. Two novel secoergosterols from the fungus Tylopilus plumbeoviolaceus. J. Nat. Prod. 2000, 63, 534–536. [Google Scholar] [CrossRef] [PubMed]
  132. Zhao, Z.Z.; Chen, H.P.; Huang, Y.; Zhang, S.B.; Li, Z.H.; Feng, T.; Liu, J.K. Bioactive polyketides and 8,14-seco-ergosterol from fruiting bodies of the ascomycete Daldinia childiae. Phytochemistry 2017, 142, 68–75. [Google Scholar] [CrossRef] [PubMed]
  133. Cui, C.M.; Li, X.M.; Meng, L.; Li, C.S.; Huang, C.G.; Wang, B.G. 7-Nor-ergosterolide, a pentalactone-containing norsteroid and related steroids from the marine-derived endophytic Aspergillus ochraceus EN-31. J. Nat. Prod. 2010, 73, 1780–1784. [Google Scholar] [CrossRef]
  134. Onodera, H.; Ichimura, M.; Baba, K.; Agatsuma, T.; Sasho, S.; Suzuki, M.; Iwamoto, S.; Kakita, S. PCT Int. Appl. WO 2009096445, Nerve Trunk Cell Propagation Accelerator, 06.08.2009; Kyowa Hakko Kirin Co., Ltd.: Tokyo, Japan.
  135. Kazlauskas, R.; Murphy, P.T.; Ravi, B.N.; Sanders, R.L.; Wells, R.J. Spermidine derivatives and 9,11-secosteroids from a soft coral (Sinularia sp.). Austral. J. Chem. 1982, 35, 69–75. [Google Scholar] [CrossRef]
  136. Bonini, C.; Cooper, C.B.; Kazlauskas, R.; Wells, R.J.; Djerassi, C. Minor and trace sterols in marine invertebrates. 41. Structure and stereochemistry of naturally occurring 9,11-seco sterols. J. Org. Chem. 1983, 48, 2108–2111. [Google Scholar] [CrossRef]
  137. Weng, J.R.; Chiu, C.F.; Sheu, J.H. A sterol from soft coral induces apoptosis and autophagy in MCF-7 breast cancer cells. Mar. Drugs 2018, 16, 238. [Google Scholar] [CrossRef] [Green Version]
  138. Chang, Y.C.; Lai, K.H.; Kumar, S.; Chen, P.J.; Wu, Y.H.; Lai, C.L. 1HNMR-Based Isolation of Anti-Inflammatory 9,11-secosteroids from the octocoral Sinularia leptoclados. Mar. Drugs 2020, 18, 271. [Google Scholar] [CrossRef]
  139. Hirsch, A.L. Industrial aspects of vitamin D. In Vitamin, D., 3rd ed.; Feldman, D., Pike, J.W., Adams, J.S., Eds.; Academic Press: San Diego, CA, USA, 2011; pp. 73–93. [Google Scholar]
  140. Teichmann, A.; Dutta, P.C.; Staffas, A.; Jagerstäd, M. Sterol and vitamin D2 concentrations in cultivated and wild grown mushrooms: Effect of UV radiation. LWT Food Sci. Technol. 2007, 40, 815–822. [Google Scholar] [CrossRef]
  141. Koyyalamudi, S.R.; Jeong, S.C.; Song, C.H.; Cho, K.Y.; Pang, G. Vitamin D2 formation and bioavailability from Agaricus bisporus button mushrooms treated with ultraviolet irradiation. J. Agric. Food Chem. 2009, 57, 3351–3355. [Google Scholar] [CrossRef]
  142. Koyyalamudi, S.R.; Jeong, S.C.; Pang, G.; Teal, A.; Biggs, T. Concentration of vitamin D2 in white button mushrooms (Agaricus bisporus) exposed to pulsed UV light. J. Food Comp. Anal. 2011, 24, 976–979. [Google Scholar] [CrossRef]
  143. Phillips, K.M.; Ruggio, D.M.; Horst, R.L.; Minor, B.; Simon, R.R.; Feeney, M.J.; Byrdwell, W.C.; Haytowitz, D.B. Vitamin D and sterol composition of 10 types of mushrooms from retail suppliers in the United States. J. Agric. Food Chem. 2011, 59, 7841–7853. [Google Scholar] [CrossRef]
  144. Jasinghe, V.J.; Perera, C.O. Ultraviolet irradiation: The generator of vitamin D2 in edible mushrooms. Food Chem. 2006, 95, 638–643. [Google Scholar] [CrossRef]
  145. Roberts, J.S.; Teichert, A.; McHugh, T.H. Vitamin D2 formation from post-harvest UV-B treatment of mushrooms (Agaricus bisporus) and retention during storage. J. Agric. Food Chem. 2008, 56, 4541–4544. [Google Scholar] [CrossRef]
  146. Shen, Y.C.; Cheng, Y.B.; Kobayashi, J.; Kubota, T.; Takahashi, Y.; Mikami, Y.; Ito, J.; Lin, Y.S. Nitrogen-containing verticillene diterpenoids from the Taiwanese soft coral Cespitularia taeniata. J. Nat. Prod. 2007, 70, 1961–1965. [Google Scholar] [CrossRef]
  147. Lakshmi, V.; Kumar, R. Metabolites from Sinularia species. Nat. Prod. Res. 2009, 23, 801–850. [Google Scholar] [CrossRef]
  148. Kulda, V. Vitamin D metabolism. Vnitr Lek. 2012, 58, 400–404. [Google Scholar]
  149. Windaus, A.; Schenck, F.R.; Werder, F.V. The anti-rachitically active irradiation product from 7-dehydro-cholesterol. Hoppe-Seyler’s Zeitsch. Physiol. Chem. 1936, 241, 100–103. [Google Scholar] [CrossRef]
  150. Wanga, T.; Bengtsson, G.; Kärnefeltd, I.; Björn, L.O. Provitamins and vitamins D2 and D3 in Cladina spp. over a latitudinal gradient: Possible correlation with UV levels. J. Photochem. Photobiol. 2001, 62B, 118–122. [Google Scholar] [CrossRef] [Green Version]
  151. Horst, R.L.; Reinhardt, T.A.; Russell, J.R.; Napoli, J.L. The isolation and identification of vitamin D2 and vitamin D3 from Medicago sativa (Alfalfa plant). Arch. Biochem. Biophys. 1984, 231, 67–71. [Google Scholar] [CrossRef]
  152. World Health Organization. World Health Organization Model List of Essential Medicines: 21st List 2019; World Health Organization: Geneva, Switzerland, 2019. [Google Scholar]
  153. Trump, D.L.; Aragon-Ching, J.B. Vitamin D in prostate cancer. Asian J. Androl. 2018, 20, 244–252. [Google Scholar] [CrossRef]
  154. Laaksi, I. Vitamins, infectious and chronic disease during adulthood and aging Vitamin D and respiratory infection in adults. Proceed. Nutr. Soc. 2012, 71, 90–97. [Google Scholar] [CrossRef] [Green Version]
  155. Saikia, S.; Kolita, B.; Dutta, P.P.; Dutta, D.J.; Neipihoi, S.; Nath, S. Marine steroids as potential anticancer drug candidates: In silico investigation in search of inhibitors of Bcl-2 and CDK-4/Cyclin D1. Steroids 2015, 102, 7–16. [Google Scholar] [CrossRef]
  156. Dembitsky, V.M. Anticancer activity of natural and synthetic acetylenic lipids. Lipids 2006, 41, 883–924. [Google Scholar] [CrossRef]
  157. Zhang, H.; Zhao, Z.; Wang, H. Cytotoxic natural products from marine sponge-derived microorganisms. Mar. Drugs 2017, 15, 68. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  158. Mioso, R.; Marante, F.J.T.; Bezerra, R.D.S.; Borges, F.V.P.; Santos, B.V.; Laguna, I.H.B.D. Cytotoxic compounds derived from marine sponges, A review (2010–2012). Molecules 2017, 22, 208. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  159. Dembitsky, V.M.; Rezanka, T.; Srebnik, M. Lipid compounds of freshwater sponges: Family Spongillidae, class Demospongiae. Chem. Phys. Lipids 2003, 123, 117–155. [Google Scholar] [CrossRef]
  160. Xu, S.; Liao, X.; Du, B.; Zhou, X.; Huang, Q.; Wu, C. A series of new 5,6-epoxysterols from a Chinese sponge Ircinia aruensis. Steroids 2008, 73, 568–573. [Google Scholar]
  161. Li, T.; Wang, N.; Zhang, T.; Zhang, B.; Sajeevan, T.P.; Valsamma, J.; Armstrong, L.; He, S.; Yan, X.; Naman, C.B. A systematic review of recently reported marine derived natural product kinase inhibitors. Mar. Drugs 2019, 17, 493. [Google Scholar] [CrossRef] [Green Version]
  162. Zhang, H.J.; Yi, Y.H.; Yang, F.; Chen, W.S.; Lin, H.W. Sesterterpenes and a new sterol from the marine sponge Phyllospongia foliascens. Molecules 2010, 15, 834–841. [Google Scholar]
  163. Afiyatullov, S.S.; Kalinovsky, A.I.; Antonov, A.S.; Ponomarenko, L.P. Isolation and structures of erylosides from the Carribean sponge Erylus goffrilleri. J. Nat. Prod. 2007, 70, 1871–1877. [Google Scholar] [CrossRef]
  164. Anjaneyulu, A.S.R.; Krishna Murthy, M.V.R.; Gowri, P.M. Novel epoxy steroids from the Indian ocean soft coral Sarcophyton crassocaule. J. Nat. Prod. 2000, 63, 112–118. [Google Scholar]
  165. Funel, C.; Berrué, F.; Roussakis, C.; Fernandez Rodriguez, R.; Amade, P. New cytotoxic steroids from the Indian ocean sponge Axinella cf. bidderi. J. Nat. Prod. 2004, 67, 491–494. [Google Scholar]
  166. Dembitsky, V.M. Bioactive fungal endoperoxides. Med. Mycol. 2015, 1, 1–7. [Google Scholar]
  167. Dembitsky, V.M. Astonishing diversity of natural peroxides as potential therapeutic agents. J. Mol. Genet. Med. 2015, 9, 1000163. [Google Scholar]
  168. Dembitsky, V.M. Bioactive peroxides as potential therapeutic agents. Eur. J. Med. Chem. 2008, 43, 223–251. [Google Scholar]
  169. Kyasa, S.K. New Methods for Synthesis of Organic Peroxides and Application of Peroxide Electrophiles to Synthesis of Functionalized Ethers. Ph.D. Thesis, University of Nebraska-Lincoln, Lincoln, NE, USA, 2005. [Google Scholar]
  170. Klussmann, M. Alkenyl and aryl peroxides. Chemistry 2018, 24, 4480–4496. [Google Scholar]
  171. Dembitsky, V.M.; Gloriozova, T.A.; Poroikov, V.V. Natural peroxy anticancer agents. Mini-Rev. Med. Chem. 2007, 7, 571–589. [Google Scholar] [CrossRef] [PubMed]
  172. Dembitsky, V.; Shkrob, I.; Hanus, L.O. Ascaridole and related peroxides from the genus Chenopodium. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2008, 152, 209–215. [Google Scholar] [CrossRef] [PubMed]
  173. Liu, D.Z.; Liu, J.K. Peroxy natural products. Nat. Prod. Bioprospect. 2013, 3, 161–206. [Google Scholar] [CrossRef] [Green Version]
  174. Thao, N.P.; Cuong, N.X.; Luyen, B.T.T.; Nam, N.H. Steroidal constituents from the starfish Astropecten polyacanthus and their anticancer effects. Chem. Pharm. Bull. 2013, 61, 1044–1051. [Google Scholar] [CrossRef] [Green Version]
  175. Seo, Y.W.; Rho, J.R.; Cho, K.W.; Sim, C.J.; Shin, J.H. Isolation of epidioxysteroids from a sponge of the genus Tethya. Bull. Korean Chem. Soc. 1997, 18, 631–635. [Google Scholar]
  176. Gunatilaka, A.A.L.; Gopichand, Y.; Schmitz, F.J.; Djerassi, C. Minor and trace sterols in marine invertebrates. 26. Isolation and structure elucidation of nine new 5,8-epidoxy sterols from four marine organisms. J. Org. Chem. 1981, 46, 3860–3866. [Google Scholar] [CrossRef]
  177. Gauvin, A.; Smadja, J.; Aknin, M.; Faure, R.; Gaydou, E.M. Isolation of bioactive 5α,8α-epidioxy sterols from the marine sponge Luffariella cf. variabilis. Can. J. Chem. 2000, 78, 986–992. [Google Scholar] [CrossRef]
  178. Sheikh, Y.M.; Djerassi, C. Steroids from sponges. Tetrahedron 1974, 30, 4095–4103. [Google Scholar] [CrossRef]
  179. Zheng, W.; Liu, T.; Xiang, X.; Gu, Q. Sterol composition in field-grown and cultured mycelia of Inonotus obliquus. Yaoxue Xuebao 2007, 42, 750–756. [Google Scholar]
  180. Zhang, Y.; Pei, L.; Gao, L.; Huang, Q.; Qi, J. A neuritogenic compound from Tremella fuciformis. Zhongguo Zhong Yao Za Zhi 2011, 36, 2358–2360. [Google Scholar]
  181. Shi, X.W.; Li, X.J.; Gao, J.M.; Zhang, X.C. Fasciculols H and I, two lanostane derivatives from Chinese mushroom Naematoloma fasciculare. Chem. Biodivers. 2011, 8, 1864–1870. [Google Scholar] [CrossRef] [PubMed]
  182. Yaoita, Y.; Amemiya, K.; Ohnuma, H.; Furumura, K.; Masaki, A.; Matasuki, T.; Kikuchi, M. Sterol constituents from five edible mushrooms. Chem. Pharm. Bull. 1998, 46, 944–950. [Google Scholar] [CrossRef] [Green Version]
  183. Yue, J.M.; Chen, C.N.; Lin, Z.W.; Sun, H.D. Sterols from the fungus Lactarium volemus. Phytochemistry 2001, 56, 801–806. [Google Scholar] [CrossRef]
  184. Zang, M.; Ying, J.Z. Economic Fungi in the South West of China; Scientific Press: Beijing, China, 1994. [Google Scholar]
  185. Greca, M.D.; Fiorentino, A.; Molinaro, A.; Monaco, P.; Previtera, L. Hydroperoxysterols in Arum italicum. Nat. Prod. Lett. 1994, 5, 7–14. [Google Scholar] [CrossRef]
  186. Wu, S.B.; Bao, Q.Y.; Wang, W.X.; Zhao, Y.; Xia, G. Cytotoxic triterpenoids and steroids from the bark of Melia azedarach. Planta Med. 2011, 77, 922–928. [Google Scholar] [CrossRef]
  187. Ponce, M.A.; Ramirez, J.A.; Galagovsky, L.R.; Gros, E.G.; Erra-Balsells, R. A new look into the reaction between ergosterol and singlet oxygen in vitro. Photochem. Photobiol. Sci. 2002, 1, 749–756. [Google Scholar] [CrossRef]
  188. Bocking, T.; Barrow, K.D.; Netting, A.G.; Chilcott, T.C.; Coster, H.G.L.; Hofer, M. Effects of singlet oxygen on membrane sterols in the yeast Saccharomyces cerevisiae. Eur. J. Biochem. 2000, 267, 1607–1618. [Google Scholar] [CrossRef] [Green Version]
  189. Banskota, A.H.; Tezuka, Y.; Phung, L.K.; Tran, K.Q.; Saiki, I. Cytotoxic cycloartane-type triterpenes from Combretum quadrangulare. Bioorg. Med. Chem. Lett. 1998, 8, 3519–3524. [Google Scholar] [CrossRef]
  190. Bankota, A.H.; Tezuka, Y.; Tran, K.Q.; Tanaka, K.; Saiki, I.; Kadota, S. Thirteen novel cycloartane-type triterpenes from Combretum quadrangulare. J. Nat. Prod. 2000, 63, 57–64. [Google Scholar] [CrossRef]
  191. Roy, R.; Raj, K.; Singh, K.; Jash, S.K.; Sarkar, A.; Gorai, D. Combretum quadrangulare (Combretaceae): Phytochemical constituents and biological activity. Indo Amer. J. Pharm. Res. 2014, 4, 3416–3427. [Google Scholar]
  192. Asai, T.; Hara, N.; Fujimoto, Y. Fatty acid derivatives and dammarane triterpenes from the glandular trichome exudates of Ibicella lutea and Proboscidea louisiana. Phytochemistry 2010, 71, 877–894. [Google Scholar] [CrossRef]
  193. Lee, I.S.; Oh, S.R.; Ahn, K.S.; Lee, H.K. Semialactone, isofouquierone peroxide and fouquierone, three new dammarane triterpenes from Rhus javanica. Chem. Pharm. Bull. 2001, 49, 1024–1029. [Google Scholar] [CrossRef] [Green Version]
  194. Abdel Bar, F.M.; Zaghloul, A.M.; Bachawal, S.V.; Sylvester, P.W.; Ahmad, K.F.; El Sayed, K.A. Antiproliferative triterpenes from Melaleuca ericifolia. J. Nat. Prod. 2008, 71, 1787–1790. [Google Scholar] [CrossRef]
  195. Chiamg, Y.M.; Kuo, Y.H. New peroxy triterpenes from the aerial roots of Ficus macrocarpa. J. Nat. Prod. 2001, 64, 436–439. [Google Scholar] [CrossRef]
  196. Sikorsky, T.V.; Ermolenko, E.V.; Gloriozova, T.A.; Dembitsky, V.M. Mini Review: Anticancer activity of diterpenoid peroxides. Vietnam J. Chem. 2020, 58, 273–280. [Google Scholar] [CrossRef]
  197. Dembitsky, V.M.; Yaremenko, I.A. Stable and unstable 1,2-dioxolanes: Origin, synthesis, and biological activities. Sci. Synth. Knowl. Updates 2020, 38, 277–321. [Google Scholar] [CrossRef]
  198. Dembitsky, V.M.; Vil, V.A. Medicinal chemistry of stable and unstable 1,2-dioxetanes: Origin, formation, and biological activities. Sci. Synth. Knowl. Updates 2020, 38, 333–381. [Google Scholar] [CrossRef]
  199. Phillipson, J.D.; Wright, C.W. Antiprotozoal agents from plant sources. Planta Med. 1991, 57, S53–S59. [Google Scholar] [CrossRef] [PubMed]
  200. Moss, G.P. The nomenclature of steroids. Eur. J. Biochem. 1989, 186, 429–458. [Google Scholar]
  201. Burger, A. Cyclopropane compounds of biological interest. Prog. Drug Res. 1971, 15, 227–270. [Google Scholar]
  202. Schoenheimer, R.; Evans, E.A., Jr. The chemistry of the steroids. Ann. Rev. Biochem. 1937, 6, 139–162. [Google Scholar] [CrossRef]
  203. Dembitsky, V.M.; Gloriozova, T.A. Astonishing diversity of carbon-bridged steroids and their biological activities: A brief review. Eur. J. Biotechnol. Biosci. 2018, 6, 6–23. [Google Scholar]
  204. Jacobs, H.J.C. Photochemistry of conjugated trienes: Vitamin D revisited. Pure Appl. Chem. 1995, 67, 63–70. [Google Scholar] [CrossRef] [Green Version]
  205. Kalaras, M.D. Production of Ergocalciferol (Vitamin D2) and Related Sterols in Mushrooms with Exposure to Pulsed Ultraviolet Light. Ph.D. Thesis, Pennsylvania State University, State College, PA, USA, January 2012. [Google Scholar]
  206. Mitome, H.; Shirato, N.; Hoshino, A.; Miyaoka, H.; Yamada, Y.; Yamada, Y.; Van Soest, R.W.M. New polyhydroxylated sterols stylisterols A–C and a novel 5, 19-cyclosterol hatomasterol from the Okinawan marine sponge Stylissa sp. Steroids 2005, 70, 63–70. [Google Scholar] [CrossRef]
  207. Calabro, K.; Kalahroodi, E.L.; Rodrigues, D.; Díaz, C.; Cruz, M.D.L.; Cautain, B.; Laville, R. Poecillastrosides, steroidal saponins from the Mediterranean deep-sea sponge Poecillastra compressa (Bowerbank, 1866). Mar. Drugs 2017, 15, 199. [Google Scholar] [CrossRef] [Green Version]
  208. Giner, J.-L.; Gunasekera, S.P.; Pomponi, S.A. Sterols of the marine sponge Petrosia weinbergi: Implications for the absolute configurations of the antiviral orthoesterols and weinbersterols. Steroids 1999, 64, 820–824. [Google Scholar] [CrossRef]
  209. HXinping, H.; Xiaobin, Z.; Liping, D.; Zhiwei, D.; Wenhan, L. Cycloartane triterpenes from marine green alga Cladophora fascicularis. Chin. J. Ocean. Limnol. 2006, 24, 443–448. [Google Scholar] [CrossRef]
  210. Tung, N.H.; Van Minh, C.; Ha, T.T.; Van Kiem, P.; Huong, H.T. C29-Sterols with a cyclopropane ring at C-25 and 26 from the Vietnamese marine sponge Ianthella sp. and their anticancer properties. Bioorg. Med. Chem. Lett. 2009, 19, 4584–4588. [Google Scholar] [CrossRef]
  211. Gauvin, A.; Smadja, J.; Aknin, M.; Gaydou, E.M. Cyclopropane-containing sterols in the marine sponge Petrosia spheroïda. Comp. Biochem. Physiol. 1998, 121B, 451–456. [Google Scholar] [CrossRef]
  212. Abdjul, D.B.; Yamazaki, H.; Takahashi, O.; Kirikoshi, R.; Ukai, K.; Namikoshi, M. Isopetrosynol, a new protein tyrosine phosphatase 1B inhibitor, from the marine sponge Halichondria cf. panicea collected at Iriomote Island. Chem. Pharm. Bull. 2016, 64, 733–736. [Google Scholar] [CrossRef]
  213. Umeyama, A.; Ito, S.; Yoshigaki, A.; Arihara, S. Two new 26,27-cyclosterols from the marine sponge Strongylophora corticate. J. Nat. Prod. 2000, 63, 1540–1542. [Google Scholar] [CrossRef]
  214. Minale, L.; Riccio, R.; Scalona, O.; Sodano, G.; Fattorusso, E.; Magno, S.; Mayol, L.; Santacroce, C. Metabolism in Porifera. VII. Conversion of [7,7-3H2]-fucosterol into calysterol by the sponge Calyx niceaensis. Experientia 1977, 33, 1550–1552. [Google Scholar] [CrossRef]
  215. Fatturosso, E.; Magno, S.; Mayol, L.; Santacrove, C.; Sioa, D. Calysterol: A C-29 cyclopropene-containing marine sterol from the sponge Calyx nicaensis. Tetrahedron 1975, 31, 1715–1716. [Google Scholar] [CrossRef]
  216. O’Connor, J.M.; Pu, L.; Chadha, R.K. Metallacycle annelation: Reaction of a metallacycle alpha-substituent and a vinylidene ligand to give a bicyclic metallalactone complex. J. Am. Chem. Soc. 1990, 112, 9627–9628. [Google Scholar] [CrossRef]
  217. Li, L.N.; Li, H.T.; Lang, R.W.; Itoh, T.; Sica, D.; Djerassi, C. Minor and trace sterols in marine invertebrates. 31. Isolation and structure elucidation of 23H-isocalysterol, a naturally occurring cyclopropene. Some comparative observations on the course of hydrogenolytic ring opening of steroidal cyclopropenes and cyclopropanes. J. Am. Chem. Soc. 1982, 104, 6726–6732. [Google Scholar]
  218. Gunasekera, S.P.; Cranick, S.; Pomponi, S.A. Pomponi, New sterol ester from a deep-water marine sponge, Xestospongia sp. J. Nat. Prod. 1991, 54, 1119–1122. [Google Scholar] [CrossRef]
  219. Dembitsky, V.M. Natural neo acids and neo alkanes: Their analogs and derivatives. Lipids 2006, 41, 309–340. [Google Scholar] [CrossRef]
  220. Bisel, P.; Al-Momani, L.; Müller, M. The tert-butyl group in chemistry and biology. Org. Biomol. Chem. 2008, 6, 2655–2665. [Google Scholar] [CrossRef]
  221. Dembitsky, V.M. Alkoxylipids of the Organic World. Chemistry and Biology. Ph.D. Thesis, Lomonosov University of Fine Chemical Technology, Moscow, Russia, 1996. [Google Scholar]
  222. Akihisa, A.; Inada, Y.; Ghosh, P. Compositions of triterpene alcohols of seeds and mature plants of family Cucurbitaceae. J. Am. Oil Chem. Soc. 1988, 65, 607–610. [Google Scholar] [CrossRef]
  223. Akihisa, T.; Tamura, T.; Matsumoto, T. 24-Methylene-25-methyllathosterol: A sterol from Sicyos angulatus. Phytochemistry 1987, 26, 575–577. [Google Scholar] [CrossRef]
  224. Rahimi, R.; Shams-Ardekani, M.R.; Abdollahi, M. A review of the efficacy of traditional Iranian medicine for inflammatory bowel disease. World J. Gastroenterol. 2010, 16, 4504–4514. [Google Scholar] [CrossRef]
  225. Bojić, M.; Maleš, Ž.; Antolić, A.; Babić, I.; Tomičić, M. Antithrombotic activity of flavonoids and polyphenols rich plant species. Acta Pharma. 2019, 69, 483–495. [Google Scholar] [CrossRef] [Green Version]
  226. Sestili, P.; Ismail, T.; Calcabrini, C.; Guescini, M.; Catanzaro, E.; Turrini, E. The potential effects of Ocimum basilicum on health: A review of pharmacological and toxicological studies. Expert Opin. Drug Metab. Toxicol. 2018, 14, 679–692. [Google Scholar] [CrossRef]
  227. Devi, P.U. Radioprotective, anticarcinogenic and antioxidant properties of the Indian holy basil, Ocimum sanctum (Tulasi). Indian J. Exp. Biol. 2001, 39, 185–190. [Google Scholar]
  228. Ch, M.A.; Naz, S.B.; Sharif, A.; Akram, M.; Saeed, M.A. Biological and pharmacological properties of the sweet basil (Ocimum basilicum). Br. J. Pharm Res. 2015, 7, 330–339. [Google Scholar] [CrossRef]
  229. Siddiqui, B.S.; Aslam, H.; Ali, S.T. Two new triterpenoids and a steroidal glycoside from the aerial parts of Ocimum basilicum. Chem. Pharm Bull. 2007, 55, 516–519. [Google Scholar] [CrossRef] [Green Version]
  230. Li, Y. Stereo Chemical Studies on the Metabolism of Sterols by Saccharomyces Cerevisiae Strain GL7. Ph.D. Thesis, Texas Tech University, Lubbock, TX, USA, 1996. [Google Scholar]
  231. Liu, J.; Nes, W.D. Steroidal triterpenes: Design of substrate-based inhibitors of ergosterol and sitosterol synthesis. Molecules 2009, 14, 4690–4706. [Google Scholar] [CrossRef] [Green Version]
  232. Ishibashi, M.; Yamagishi, E.; Kobayashi, J. Topsentinols A-J, new sterols with highly branched side chains from marine sponge Topsentia sp. Chem. Pharm Bull. 1997, 45, 1435–1438. [Google Scholar] [CrossRef] [Green Version]
  233. Nojo, R.; Echigo, S.; Hara, N.; Fujimoto, Y. C-24 stereochemistry of marine sterols: (22E)-25,28-dimethylstigmasta-5,22,28-trien-3β-ol and 25,28-dimethylstigmasta-5,28-dien-3β-ol. Nat. Prod. Commun. 2014, 9, 1699–1704. [Google Scholar] [CrossRef] [Green Version]
  234. Li, X.; Djerassi, C. Minor and trace sterols in marine invertebrates 40. Structure and synthesis of axinyssasterol, 25-methylfucosterol and 24-ethyl-24-methylcholesterol—Novel sponge sterols with highly branched side chains. Tetrahedron Lett. 1983, 24, 665–668. [Google Scholar] [CrossRef]
  235. Shubina, L.K.; Makar’eva, T.N.; Stonik, V.A. Steroidal compounds of marine sponges. III. 24-Ethyl-25-methylcholesta-5,22-dien-3b-ol—A novel marine sterol from the sponge Halichondria sp. Khim. Prir. Soedin. 1984, 4, 464–467. [Google Scholar]
  236. Shubina, L.K.; Makar’eva, T.N.; Stonik, V.A. Steroidal compounds of marine sponges. VI. Sterols and their derivatives from Trachyopsis aplysinoides. Khim. Prir. Soedin. 1985, 5, 715–716. [Google Scholar]
  237. Fusetani, N.; Matsunaga, S.; Konosu, S. Bioactive marine metabolites. II. Halistanol sulfate, an antimicrobial novel steroid sulfate from the marine sponge Halichondria cf. moorei Bergquist. Tetrahedron Lett. 1981, 22, 1985–1988. [Google Scholar] [CrossRef]
  238. Gulavita, N.K.; Wright, A.E.; Kelly-Borges, M.; Longley, R.E. Eryloside E from an Atlantic sponge Erylus goffrilleri. Tetrahedron Lett. 1994, 35, 4299–4302. [Google Scholar] [CrossRef]
  239. Ebada, S.S.; Lin, W.H.; Proksch, P. Bioactive sesterterpenes and triterpenes from marine sponges: Occurrence and pharmacological significance. Marine Drugs 2010, 8, 313–346. [Google Scholar] [CrossRef] [Green Version]
  240. Morrison-Gardiner, S. Dominant fungi from Australian reefs. Fungal Divers. 2002, 9, 105–121. [Google Scholar]
  241. Jones, E.B.G.; Sakayaroj, J.; Suetrong, S.; Somrithipol, S.; Pang, K.L. Classification of marine Ascomycota, anamorphic taxa and Basidiomycota. Fungal Divers. 2009, 35, 1–187. [Google Scholar]
  242. El-Bondkly, E.A.M.; El-Bondkly, A.A.M.; El-Bondkly, A.A.M. Marine endophytic fungal metabolites: A whole new world of pharmaceutical therapy exploration. Heliyon 2021, 7, e06362. [Google Scholar] [CrossRef]
  243. Wang, S.K.; Dai, C.F.; Duh, C.Y. Cytotoxic pregnane steroids from the Formosan Soft Coral Stereonephthya crystalliana. J. Nat. Prod. 2006, 69, 103–106. [Google Scholar] [CrossRef]
  244. Murillo-Alvarez, J.; Encarnacion-Dimayuga, R. New bioactive pregnadiene-derived glycosides from the gulf of California gorgonian Muricea cf. austera. Pharm. Biol. 2003, 41, 531–535. [Google Scholar] [CrossRef]
  245. Anjaneyulu, A.S.R.; Rao, V.L.; Sastry, V.G. A new spiroketal steroid from Gorgonella umbraculum. Nat. Prod. Res. 2003, 17, 149–152. [Google Scholar] [CrossRef] [PubMed]
  246. Seo, Y.; Rho, J.R.; Cho, K.W.; Shin, J. Isolation of new steroidal hemiacetals from the gorgonian Euplexaura anastomosans. J. Nat. Prod. 1996, 59, 1196–1199. [Google Scholar] [CrossRef]
  247. Huang, C.Y.; Chang, C.W.; Sheu, J.H. Bioactive steroids from the Formosan soft coral Umbellulifera petasites. Mar. Drugs 2016, 14, 180. [Google Scholar] [CrossRef] [Green Version]
  248. Blunt, J.W.; Copp, B.R.; Munro, M.H.G.; Northcote, P.T.; Prinsep, M.R. Marine natural products. Nat. Prod. Rep. 2005, 22, 15–61. [Google Scholar] [CrossRef]
  249. Ngoc, N.T.; Huong, P.T.M.; Thanh, N.V.; Cuong, N.X. Steroid constituents from the soft coral Sinularia nanolobata. Chem. Pharm. Bull. 2016, 64, 1417–1419. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  250. Gebreyesus, T.; Stoilov, I.; Luo, F.T.; Djerassi, C. Minor and trace sterols in marine invertebrates 55. The isolation, structure elucidation and synthesis of ergosta-5,24(28),25-trien-3-ol. Steroids 1985, 45, 447–452. [Google Scholar] [CrossRef]
  251. Chao, C.H.; Chou, K.J.; Huang, C.Y.; Wen, Z.H.; Hsu, C.H. Steroids from the soft coral Sinularia crassa. Mar. Drugs 2012, 10, 439–450. [Google Scholar] [CrossRef]
  252. Mariottini, G.L. The role of cnidaria in drug discovery. In The Cnidaria, Past, Present and Future; Goredo, S., Dubinsky, Z., Eds.; Springer: Cham, Switzerland, 2016. [Google Scholar]
  253. Ilhan, H.A.; Pulat, C.C. Cytotoxic and antitumor compounds from marine invertebrates. Encycl. Mar. Biotechnol. 2020, 4, 2529–2584. [Google Scholar] [CrossRef]
  254. Ngoc, N.T.; Huong, P.T.M.; Van Thanh, N.; Chia, N.T.P.C. Cytotoxic steroids from the Vietnamese soft coral Sinularia conferta. Chem. Pharm. Bull. 2017, 65, 300–305. [Google Scholar] [CrossRef] [Green Version]
  255. Cuíng, N.X.; Nhiem, N.X.; Thanh, N.V. Review of chemistry and biological activity studies some marine species in Vietnam in the period 2013–2017. Vietnam J. Chem. 2018, 56, 1–19. [Google Scholar]
  256. Cardoso-Martínez, F.; de la Rosa, J.M.; Díaz-Marrero, A.R.; Darias, J. Oxysterols from an octocoral of the genus Gorgonia from the eastern Pacific of Panama. J. RSC Adv. 2013, 6, 38579–38591. [Google Scholar] [CrossRef] [Green Version]
  257. Yan, X.; Liu, J.; Leng, X.; Ouyang, H. Chemical diversity and biological activity of secondary metabolites from soft coral genus Sinularia since 2013. Mar. Drugs 2021, 19, 335. [Google Scholar] [CrossRef]
  258. Radhika, P. Chemical constituents and biological activities of the soft corals of genus Cladiella: A review. Biochem. Syst. Ecol. 2006, 34, 781–789. [Google Scholar] [CrossRef]
  259. Zubair, M.S.; Al-Footy, K.O.; Ayyad, S.-E.N.; Al-Lihaibi, S.S.; Alarif, W.M. A review of steroids from Sarcophyton species. Nat. Prod. Res. 2016, 30, 869–879. [Google Scholar] [CrossRef]
  260. Amir, F.; Koay, Y.C.; Yam, W.S. Chemical constituents, and biological properties of the marine soft coral Nephthea: A review (Part 1). Trop. J. Pharm. Res. 2012, 11, 485–498. [Google Scholar]
  261. Amir, F.; Koay, Y.C.; Yam, W.S. Chemical constituents, and biological properties of the marine soft coral Nephthea: A review (Part 2). Trop. J. Pharm. Res. 2012, 11, 499–517. [Google Scholar]
  262. Baulieu, E.E. Steroid hormones in the brain: Several mechanisms? Steroid hormone regulation of the brain. In Proceedings of the International Symposium Held at the Wenner-Gren Center, Stockholm, Sweden, 27–28 October 1980; pp. 3–14. [Google Scholar]
  263. Vest, R.S.; Pike, C.J. Gender, sex steroid hormones, and Alzheimer’s disease. Horm Behav. 2013, 63, 301–307. [Google Scholar] [CrossRef] [Green Version]
  264. Lenz, K.M.; McCarthy, M.M. Organized for sex–steroid hormones and the developing hypothalamus. Eur. J. Neurosci. 2010, 32, 2096–2104. [Google Scholar] [CrossRef] [Green Version]
  265. Tchernof, A.; Després, J.P. Sex steroid hormones, sex hormone-binding globulin, and obesity in men and women. Horm. Metab. Res. 2000, 32, 526–536. [Google Scholar] [CrossRef]
  266. Luine, V.N. Sex steroids and cognitive function. J. Neuroendocrinol. 2008, 20, 866–872. [Google Scholar] [CrossRef]
  267. Rubinow, K.B. An intracrine view of sex steroids, immunity, and metabolic regulation. Mol. Metab. 2018, 15, 92–103. [Google Scholar] [CrossRef] [PubMed]
  268. Owens, S.J.; Murphy, C.E.; Purves-Tyson, T.D.; Weickert, T.W.; Weickert, S.C. Considering the role of adolescent sex steroids in schizophrenia. J. Neuroendocrinol. 2018, 30, e12538. [Google Scholar] [CrossRef] [PubMed]
  269. Wang, S.; Dong, G.; Sheng, C. Structural simplification of natural products. Chem. Rev. 2019, 119, 4180–4220. [Google Scholar] [CrossRef] [PubMed]
  270. Nahar, L.; Sarker, S.D. A review on steroid dimers: 2011–2019. Steroids 2020, 164, 108736. [Google Scholar] [CrossRef]
  271. Sahu, P.; Gidwani, B.; Dhongade, H.J. Pharmacological activities of dehydroepiandrosterone: A review. Steroids 2020, 153, 108507. [Google Scholar] [CrossRef]
  272. Biellmann, J.-F. Enantiomeric steroids:  synthesis, physical, and biological properties. Chem. Rev. 2003, 103, 2019–2034. [Google Scholar] [CrossRef]
  273. Skoda-Földes, R.; Kollár, L. Transition-metal-catalyzed reactions in steroid synthesis. Chem. Rev. 2003, 103, 4095–4130. [Google Scholar] [CrossRef]
  274. Albano, G.D.; Amico, F.; Cocimano, G.; Liberto, A.; Maglietta, F. Adverse effects of anabolic-androgenic steroids: A literature review. Healthcare 2021, 9, 97. [Google Scholar] [CrossRef]
  275. Pope, H.G., Jr.; Kanayama, G.; Hudson, J.I.; Kaufman, M.J. Anabolic-androgenic steroids, violence, and crime: Two cases and literature review. Am. J. Addict. 2021, 30, 423–432. [Google Scholar] [CrossRef]
  276. Hearne, E.; Wazaify, M.; Van Hout, M.C.; Atkinson, A.; McVeigh, J. Anabolic-androgenic steroid use in the Eastern Mediterranean region: A scoping review of extant empirical literature. Int. J. Ment. Health Addict. 2021, 19, 1162–1189. [Google Scholar] [CrossRef] [Green Version]
  277. Shamsaei, N.; Ahmadian, N. Investigation of psychological relationship between the level of religiosity and doping susceptibility among bodybuilding athletes. Relig. Health Spring Summer 2020, 8, 30–38. [Google Scholar]
  278. Hoseini, M.; Yousefi, B.; Khazaei, A. The prevalence of anabolic-androgenic steroids abuse, knowledge and attitude of their side effects, and attitude toward them among the female bodybuilding athletes in kermanshah. J. Fasa Univ. Med. Sci. 2020, 10, 2436–2446. [Google Scholar]
  279. Murtha, R.; Heffernan, C.; Hunt, T. Definition diets and deteriorating masculinity? Bodybuilding diets in Mid-Century America. Glob. Food Hist. 2021, 7, 71–91. [Google Scholar] [CrossRef]
  280. Okano, M.; Sato, M.; Ikekita, A. Analysis of non-ketoic steroids 17α-methylepithiostanol and desoxymethyl-testosterone in dietary supplements. Drug Test. Anal. 2009, 1, 518–525. [Google Scholar]
  281. Akram, O.N.; Bursill, C.; Desai, R.; Heather, A.K.; Kazlauskas, R.; Handelsman, D.J.; Lambert, G. Evaluation of androgenic activity of nutraceutical-derived steroids using mammalian and yeast in vitro androgen bioassays. Anal. Chem. 2011, 83, 2065–2072. [Google Scholar] [CrossRef]
  282. Díaz, F.C.; Sáez-González, E.; Benlloch, S.; Álvarez-Sotomayor, D. Albumin dialysis with MARS for the treatment of anabolic steroid-induced cholestasis. Ann. Hepatol. 2016, 15, 939–943. [Google Scholar]
  283. Okuno, Y.; Nakabou, Y.; Suzuki, S.; Ichiba, S.; Sugiyama, H. Complete remission by mepitiostane in hypoplastic leukemia. Rinsho Ketsueki 1989, 30, 1280–1283. [Google Scholar]
  284. Komeno, T. Steromal 2,3-Diol Cyclic Trithiocarbonate. U.S. Patent 3,139,128, 30 June 1964. [Google Scholar]
  285. Korneno, T.; Kawanami, E. 11,12-Epithio Steroids of Pregnane Series. U.S. Patent 3160627, 25 December 1964. [Google Scholar]
  286. Komeno, T. 2,3-Epithio-Steroids and Production Thereof. U.S. Patent 3,230,215, 18 January 1966. [Google Scholar]
  287. Klimstra, P.D. Optionally 17-Hydrocarbon (Substituted), 17-Oxygenated-2,3-Epithio-5a-Androstanes. U.S. Patent 3,405,124, 25 December 1968. [Google Scholar]
  288. Hirata, M. Process for Stabilization of a Composition of 2,3-Epithio-Androstanes and Composition Obtained Thereby. U.S. Patent 3,670,080, 13 June 1972. [Google Scholar]
  289. Miyake, T.; Uchida, K.; Kakushi, H.; Nomura, Y.; Kadowaki, M. 2a,3a-epithio-5a-androstan-17b-yl 1-methoxycyclopentyl ether (10361-S), a new orally active anabolic-androgenic steroid. Jpn. J. Pharmacol. 1974, 24, 551–558. [Google Scholar] [CrossRef] [Green Version]
  290. Kurachi, K.; Aono, T.; Tomoyama, J.; Matsumoto, K.; Nakasima, A. Effects of 2,3-epithio-5-androstan-17-ol (epitiostanol) on hypothalamo-pituitary-gonadal axis in humans. Acta Obstet. Gynaecol. Jpn. 1975, 22, 42–48. [Google Scholar]
  291. Li, X.; Rhee, D.K.; Malhotra, R.; Mayeur, C.; Hurst, L.A.; Ager, E. Progesterone receptor membrane component-1 regulates hepcidin biosynthesis. J. Clin. Investig. 2016, 126, 389–401. [Google Scholar] [CrossRef]
  292. Kang, L.; Li, X.Q.; Chen, C.X.; Wang, F.R. Research progress on structure modification and biological activity of 18β-glycyrrhetinic acid. Curr. Opin. Compl. Alternat. Med. 2014, 1, e00008. [Google Scholar]
  293. Wu, S.; Wang, W.; Dou, J.H. Research progress on the protective effects of licorice-derived 18β-glycyrrhetinic acid against liver injury. Acta Pharmacol. Sin. 2021, 42, 18–26. [Google Scholar] [CrossRef]
  294. Dembitsky, V.M.; Gloriozova, T.A.; Poroikov, V.V. Pharmacological activities of epithio steroids. J. Pharm. Res. Int. 2017, 18, 1–19. [Google Scholar] [CrossRef]
  295. Huang, M.; Xie, X.; Gong, P.; Wei, Y.; Du, H.; Xu, Y. A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects. Eur. J. Med. Chem. 2020, 188, 111991. [Google Scholar] [CrossRef]
  296. Conor, R. Selenium in Food and Health; Springer: Boston, MA, USA, 2006. [Google Scholar]
  297. Kang, D.; Lee, J.; Wu, C. The role of selenium metabolism and selenoproteins in cartilage homeostasis and arthropathies. Exp. Mol. Med. 2020, 52, 1198–1208. [Google Scholar] [CrossRef]
  298. Terry, N.; Zayed, A.M.; De Souza, M.P.; Tarun, A.S. Selenium in higher plants. Ann. Rev. Plant Physiol. Plant Mol. Biol. 2000, 51, 401–432. [Google Scholar] [CrossRef] [Green Version]
  299. Pyrzynska, K.; Sentkowska, A. Selenium in plant foods: Speciation analysis, bioavailability, and factors affecting composition. Crit. Rev. Food Sci. Nutrit. 2021, 61, 1340–1352. [Google Scholar] [CrossRef]
  300. Pilon-Smits, E.A.H. Selenium in plants. Prog. Bot. 2015, 76, 93–106. [Google Scholar]
  301. Nogueira, C.W.; Barbosa, N.V.; Rocha, J.B.T. Toxicology and pharmacology of synthetic organoselenium compounds: An update. Arch. Toxicol 2021, 95, 1179–1226. [Google Scholar] [CrossRef]
  302. Ranu, B.C.; Banerjee, B. Organoselenium Chemistry; De Gruyter: Berlin, Germany; Boston, MA, USA, 2020. [Google Scholar]
  303. Li, Q.S.; Wu, D.M.; Zhu, B.C.; Wang, Y.G. Organic selenium resin in solid phase synthesis and its application in constructing medicinally relevant small organic molecules. Mini Rev. Med. Chem. 2013, 13, 854–869. [Google Scholar] [CrossRef] [PubMed]
  304. Dembitsky, V.M.; Gloriozova, T.A.; Poroikov, V.V. Biological activities of organometalloid (As, At, B, Ge, Si, Se, Te) steroids. J. App. Pharm. Sci. 2017, 7, 184–202. [Google Scholar]
  305. Wirth, T. Organoselenium Chemistry: Synthesis and Reactions; John Wiley & Sons, Inc.: Weinheim, Germany, 2011. [Google Scholar]
  306. Ibrahim-Ouali, M. Total synthesis of steroids and heterosteroids from BISTRO. Steroids 2015, 98, 9–28. [Google Scholar] [CrossRef] [PubMed]
  307. Ibrahim-Ouali, M. First total synthesis of 11-selena steroids. Tetrahedron Lett. 2009, 50, 1607–1609. [Google Scholar] [CrossRef]
  308. Ibrahim-Ouali, M. First total synthesis of 11-tellura steroids. Tetrahedron Lett. 2010, 51, 3610–3612. [Google Scholar] [CrossRef]
  309. Ibrahim-Ouali, M.; Romero, E.; Bouleghlem, H. First total syntheses of (±)-3-aza-11-selena and (±)-3-aza-11-tellura steroids. Tetrahedron 2011, 67, 3668–3676. [Google Scholar] [CrossRef]
  310. Santi, C. Organoselenium Chemistry: Between Synthesis and Biochemistry; Bentham Science Publishers: Sharjah, United Arab Emirates, 2014. [Google Scholar]
  311. Knapp, F.F. The synthesis of 123Te-labeled 17β-hydroxy-2-tellura-A-nor-5α-androstane. J. Label. Comp. Radiopharm. 1980, 17, 81–91. [Google Scholar] [CrossRef]
  312. Leimbach, D.; Karls, J.; Guo, Y.; Ahmed, R.; Ballof, J.; Bengtsson, L.; Pamies, F.B.; Borschevsky, A. The electron affinity of astatine. Nat. Commun. 2020, 11, 3824. [Google Scholar] [CrossRef]
  313. Kugler, H.K.; Keller, C. At Astatine; Springer: Berlin/Heidelberg, Germany, 1985. [Google Scholar]
  314. Eychenne, R.; Bouvry, C.; Bourgeois, M.; Loyer, P.; Benoist, E.; Lepareur, N. Overview of radiolabeled somatostatin analogs for cancer imaging and therapy. Molecules 2020, 25, 4012. [Google Scholar] [CrossRef]
  315. Visser, G.W.M.; Diemer, E.L.; Kaspersen, F.M. The preparation of aromatic astatine compounds through aromatic mercury compound’s part II: Astatination of pyrimidines and steroids. J. Label. Comp. Radiopharm. 1981, 18, 799–807. [Google Scholar] [CrossRef]
  316. Liu, B.L.; Jin, Y.T.; Liu, Z.H.; Luo, C.; Kojima, M.; Maeda, M. Halogen exchanges using crown ethers: Synthesis and preliminary biodistribution of 6-(211At)-astatomethyl-19-norcholest-5(10)-en-3beta-ol. Int. J. Appl. Radiat. Isot. 1985, 36, 561–563. [Google Scholar]
Marinedrugs 19 00650 g001 550
Figure 1. Bioactive aromatic steroids demonstrating with dominance of antihypercholesterolemia and antiovulation activity.
Figure 1. Bioactive aromatic steroids demonstrating with dominance of antihypercholesterolemia and antiovulation activity.
Marinedrugs 19 00650 g001
Marinedrugs 19 00650 g002 550
Figure 2. The 3D graph (X (a) and Y (b) views) shows the predicted and calculated antiovulation activity of aromatic steroids (compound numbers: 7, 9, 1, 8, and 10) showing the highest degree of confidence, more than 92.5%. These steroids are derived from animals, including humans, as well as the extract of bark from the main wooden rod of ketapang Terminalia catappa, and can be used in clinical medicine as potential agents with strong ovulation inhibitors. The units of measurement of the x–y digits (Cos–Sin or Sin–Sin) are the relative dimensions that the Origin Pro 2021 graphics program chooses independently, depending on the data obtained by the PASS program. On the 3D graphs, the Origin Pro software in red indicates the maximum biological activity of an individual steroid, and blue indicates the minimum activity.
Figure 2. The 3D graph (X (a) and Y (b) views) shows the predicted and calculated antiovulation activity of aromatic steroids (compound numbers: 7, 9, 1, 8, and 10) showing the highest degree of confidence, more than 92.5%. These steroids are derived from animals, including humans, as well as the extract of bark from the main wooden rod of ketapang Terminalia catappa, and can be used in clinical medicine as potential agents with strong ovulation inhibitors. The units of measurement of the x–y digits (Cos–Sin or Sin–Sin) are the relative dimensions that the Origin Pro 2021 graphics program chooses independently, depending on the data obtained by the PASS program. On the 3D graphs, the Origin Pro software in red indicates the maximum biological activity of an individual steroid, and blue indicates the minimum activity.
Marinedrugs 19 00650 g002
Marinedrugs 19 00650 g003 550
Figure 3. The 3D graph shows the predicted pharmacological activities of 2-hydroxyestrone (7). 2-Hydroxyestrone (2-OHE1) or 2.3-estracatechol, also known as estra-1,3,5(10)-trien-2,3-diol-17-one, is an endogenous, naturally occurring catechol estrogen that was first isolated from human urine more than 60 years ago [106], apparently as a product of estrone and estradiol metabolism. According to the PASS data, 2-hydroxyestrone is the strongest ovulation inhibitor among aromatic steroids. In addition, it is a cardiovascular analeptic and can be used as a drug for the treatment and prevention of male reproductive dysfunction, menopausal disorders in women, as well as treatment of muscular dystrophy.
Figure 3. The 3D graph shows the predicted pharmacological activities of 2-hydroxyestrone (7). 2-Hydroxyestrone (2-OHE1) or 2.3-estracatechol, also known as estra-1,3,5(10)-trien-2,3-diol-17-one, is an endogenous, naturally occurring catechol estrogen that was first isolated from human urine more than 60 years ago [106], apparently as a product of estrone and estradiol metabolism. According to the PASS data, 2-hydroxyestrone is the strongest ovulation inhibitor among aromatic steroids. In addition, it is a cardiovascular analeptic and can be used as a drug for the treatment and prevention of male reproductive dysfunction, menopausal disorders in women, as well as treatment of muscular dystrophy.
Marinedrugs 19 00650 g003
Marinedrugs 19 00650 g004 550
Figure 4. The 3D graph showing the predicted and calculated antihypercholesterolemic activity of aromatic steroids (compound numbers: 6, 13, 11, 14, 15, and 19) with the highest degree of confidence, more than 94.6%. These steroids have been obtained from a variety of natural sources, including plant, fungal, and marine invertebrate extracts, and appear to be useful in clinical medicine as potential agents with potent antihypercholesterolemic activity.
Figure 4. The 3D graph showing the predicted and calculated antihypercholesterolemic activity of aromatic steroids (compound numbers: 6, 13, 11, 14, 15, and 19) with the highest degree of confidence, more than 94.6%. These steroids have been obtained from a variety of natural sources, including plant, fungal, and marine invertebrate extracts, and appear to be useful in clinical medicine as potential agents with potent antihypercholesterolemic activity.
Marinedrugs 19 00650 g004
Marinedrugs 19 00650 g005 550
Figure 5. The 3D graph shows the predicted pharmacological activities of estriol 3-glucuronide (6). The water-soluble conjugate of estriol, also known as estriol 3-β-D-glucosiduronic acid, is a naturally occurring steroidal estrogen containing β-D-glucopyranuronic acid that was first discovered and isolated from the urine of women in the late 1930s [107,108,109]. According to the PASS data, estrone glucuronide, in addition to the main antihypercholesterolemic activity (97.3%), is also a potent regulator of lipid metabolism with a reliability of 90.7% and can be used to treat acute neurological disorders (92.2%).
Figure 5. The 3D graph shows the predicted pharmacological activities of estriol 3-glucuronide (6). The water-soluble conjugate of estriol, also known as estriol 3-β-D-glucosiduronic acid, is a naturally occurring steroidal estrogen containing β-D-glucopyranuronic acid that was first discovered and isolated from the urine of women in the late 1930s [107,108,109]. According to the PASS data, estrone glucuronide, in addition to the main antihypercholesterolemic activity (97.3%), is also a potent regulator of lipid metabolism with a reliability of 90.7% and can be used to treat acute neurological disorders (92.2%).
Marinedrugs 19 00650 g005
Marinedrugs 19 00650 g006 550
Figure 6. Bioactive natural, semi-synthetic, and synthetic steroid phosphate esters.
Figure 6. Bioactive natural, semi-synthetic, and synthetic steroid phosphate esters.
Marinedrugs 19 00650 g006
Marinedrugs 19 00650 g007 550
Figure 7. The 3D graph showing the predicted pharmacological activities of tremasterol A (21). Data from the PASS program show that phosphated steroid glycoside named tremasterol A exhibits 20 different biological activities, with dominant properties as a wound healing agent. Interestingly, tremasterol A is isolated from the starfish Trenzaster novaecaledoniae. This is a rare occasion when glycosides from starfish demonstrate such beneficial biological activities.
Figure 7. The 3D graph showing the predicted pharmacological activities of tremasterol A (21). Data from the PASS program show that phosphated steroid glycoside named tremasterol A exhibits 20 different biological activities, with dominant properties as a wound healing agent. Interestingly, tremasterol A is isolated from the starfish Trenzaster novaecaledoniae. This is a rare occasion when glycosides from starfish demonstrate such beneficial biological activities.
Marinedrugs 19 00650 g007
Marinedrugs 19 00650 g008 550
Figure 8. The 3D graph showing the predicted pharmacological activities of the sitostanol derivative (30). This drug has antihypercholesterolemic and antihyperlipoproteinemic properties that help lower cholesterol levels in the human body and reduce the risk of strokes and heart attacks. In addition, the drug is a strong cholesterol absorption inhibitor with a confidence level of 95.7% and a regulator of lipid metabolism with a confidence level of 95.4% and can be used to treat acute neurological disorders.
Figure 8. The 3D graph showing the predicted pharmacological activities of the sitostanol derivative (30). This drug has antihypercholesterolemic and antihyperlipoproteinemic properties that help lower cholesterol levels in the human body and reduce the risk of strokes and heart attacks. In addition, the drug is a strong cholesterol absorption inhibitor with a confidence level of 95.7% and a regulator of lipid metabolism with a confidence level of 95.4% and can be used to treat acute neurological disorders.
Marinedrugs 19 00650 g008
Marinedrugs 19 00650 g009 550
Figure 9. Secosteroids showing activity as lipid metabolism regulators.
Figure 9. Secosteroids showing activity as lipid metabolism regulators.
Marinedrugs 19 00650 g009
Marinedrugs 19 00650 g010 550
Figure 10. The 3D graph shows the predicted pharmacological activities of compound (40). This secosteroid is characterized by antihypercholesterolemic properties. In addition, it exhibits hepatoprotective properties, and it is an inhibitor of cell proliferation, which de facto can prevent several pathological diseases such as atherosclerosis, rheumatoid arthritis, psoriasis, idiopathic pulmonary fibrosis, scleroderma, and liver cirrhosis.
Figure 10. The 3D graph shows the predicted pharmacological activities of compound (40). This secosteroid is characterized by antihypercholesterolemic properties. In addition, it exhibits hepatoprotective properties, and it is an inhibitor of cell proliferation, which de facto can prevent several pathological diseases such as atherosclerosis, rheumatoid arthritis, psoriasis, idiopathic pulmonary fibrosis, scleroderma, and liver cirrhosis.
Marinedrugs 19 00650 g010
Marinedrugs 19 00650 g011 550
Figure 11. The 3D graph showing the predicted pharmacological activities of ergocalciferol (39). A secosterol hormone called ergocalciferol was first isolated as a radiation product of 7-dehydrocholesterol and described in 1936 by Windaus and co-workers [149]. Ergocalciferol is an important drug and is recommended by the World Health Organization. In addition, it has anticancer, anti-inflammatory, and antieczema properties, and can also be recommended as an antihypercholesterolemic agent and an agent against Parkinson’s disease. Certain foods, such as breakfast cereals and margarine, contain ergocalciferol in some countries, and it is found in the lichen Cladina arbuscula and alfalfa (Medicago sativa) [150,151,152,153,154].
Figure 11. The 3D graph showing the predicted pharmacological activities of ergocalciferol (39). A secosterol hormone called ergocalciferol was first isolated as a radiation product of 7-dehydrocholesterol and described in 1936 by Windaus and co-workers [149]. Ergocalciferol is an important drug and is recommended by the World Health Organization. In addition, it has anticancer, anti-inflammatory, and antieczema properties, and can also be recommended as an antihypercholesterolemic agent and an agent against Parkinson’s disease. Certain foods, such as breakfast cereals and margarine, contain ergocalciferol in some countries, and it is found in the lichen Cladina arbuscula and alfalfa (Medicago sativa) [150,151,152,153,154].
Marinedrugs 19 00650 g011
Marinedrugs 19 00650 g012 550
Figure 12. Bioactive α,β-epoxy steroids derived from marine sources.
Figure 12. Bioactive α,β-epoxy steroids derived from marine sources.
Marinedrugs 19 00650 g012
Marinedrugs 19 00650 g013 550
Figure 13. The 3D graph shows the predicted and calculated biological activity of α,β-epoxy steroids (compound numbers: 42, 44, and 48) showing the highest degree of confidence, more than 92.4%.
Figure 13. The 3D graph shows the predicted and calculated biological activity of α,β-epoxy steroids (compound numbers: 42, 44, and 48) showing the highest degree of confidence, more than 92.4%.
Marinedrugs 19 00650 g013
Marinedrugs 19 00650 g014 550
Figure 14. Bioactive steroid endoperoxides derived from marine sources and fungi.
Figure 14. Bioactive steroid endoperoxides derived from marine sources and fungi.
Marinedrugs 19 00650 g014
Marinedrugs 19 00650 g015 550
Figure 15. Bioactive steroid hydroperoxides derived from plants.
Figure 15. Bioactive steroid hydroperoxides derived from plants.
Marinedrugs 19 00650 g015
Marinedrugs 19 00650 g016 550
Figure 16. The 3D graph shows the predicted and calculated biological activity of steroid hydroperoxides (compound numbers: 59, 63, and 66) showing the highest degree of confidence, more than 93%.
Figure 16. The 3D graph shows the predicted and calculated biological activity of steroid hydroperoxides (compound numbers: 59, 63, and 66) showing the highest degree of confidence, more than 93%.
Marinedrugs 19 00650 g016
Marinedrugs 19 00650 g017 550
Figure 17. Bioactive CBS derived from fungi and marine sources.
Figure 17. Bioactive CBS derived from fungi and marine sources.
Marinedrugs 19 00650 g017
Marinedrugs 19 00650 g018 550
Figure 18. The 3D graph shows the predicted and calculated biological activity of carbon-bridged steroids (compound numbers: 70, 74, and 78) showing the highest degree of confidence, more than 95%.
Figure 18. The 3D graph shows the predicted and calculated biological activity of carbon-bridged steroids (compound numbers: 70, 74, and 78) showing the highest degree of confidence, more than 95%.
Marinedrugs 19 00650 g018
Marinedrugs 19 00650 g019 550
Figure 19. Bioactive neo steroids derived from plants and marine sources.
Figure 19. Bioactive neo steroids derived from plants and marine sources.
Marinedrugs 19 00650 g019
Marinedrugs 19 00650 g020 550
Figure 20. The 3D graph shows the predicted and calculated biological activity of neo steroids (compound numbers: 81, 86, 89, and 93) showing the highest degree of confidence, more than 96.9%.
Figure 20. The 3D graph shows the predicted and calculated biological activity of neo steroids (compound numbers: 81, 86, 89, and 93) showing the highest degree of confidence, more than 96.9%.
Marinedrugs 19 00650 g020
Marinedrugs 19 00650 g021 550
Figure 21. Bioactive steroids derived from soft corals.
Figure 21. Bioactive steroids derived from soft corals.
Marinedrugs 19 00650 g021
Marinedrugs 19 00650 g022 550
Figure 22. The 3D graph shows the predicted and calculated biological activity of soft coral steroids (compound numbers: 99, 101 and 104) showing the highest degree of confidence, more than 96.2%.
Figure 22. The 3D graph shows the predicted and calculated biological activity of soft coral steroids (compound numbers: 99, 101 and 104) showing the highest degree of confidence, more than 96.2%.
Marinedrugs 19 00650 g022
Marinedrugs 19 00650 g023 550
Figure 23. Bioactive epithio steroids and triterpenoid containing the thiirane group in a variety of steroid backbones.
Figure 23. Bioactive epithio steroids and triterpenoid containing the thiirane group in a variety of steroid backbones.
Marinedrugs 19 00650 g023
Marinedrugs 19 00650 g024 550
Figure 24. The 3D graph shows the predicted and calculated biological activity of triterpenod (116), which was synthesized from a natural sample of 18β-glycyrrhetinic acid, showing the highest degree of confidence as lipid metabolism regulator properties, more than 95.4%. 18β-Glycyrrhetinic acid is a β-amyrin-type pentacyclic triterpenoid derived from the herb licorice (Glycyrrhiza glabra). It is known and used as a flavoring agent and masks the bitter taste of drugs such as aloe and quinine; it is also effective in the treatment of peptic ulcer disease and has some additional pharmacological properties with possible antiviral, antifungal, antiprotozoal, and antibacterial effects.
Figure 24. The 3D graph shows the predicted and calculated biological activity of triterpenod (116), which was synthesized from a natural sample of 18β-glycyrrhetinic acid, showing the highest degree of confidence as lipid metabolism regulator properties, more than 95.4%. 18β-Glycyrrhetinic acid is a β-amyrin-type pentacyclic triterpenoid derived from the herb licorice (Glycyrrhiza glabra). It is known and used as a flavoring agent and masks the bitter taste of drugs such as aloe and quinine; it is also effective in the treatment of peptic ulcer disease and has some additional pharmacological properties with possible antiviral, antifungal, antiprotozoal, and antibacterial effects.
Marinedrugs 19 00650 g024
Marinedrugs 19 00650 g025 550
Figure 25. Bioactive synthetic selena steroids.
Figure 25. Bioactive synthetic selena steroids.
Marinedrugs 19 00650 g025
Marinedrugs 19 00650 g026 550
Figure 26. The 3D graph shows the predicted and calculated biological activity of the selena steroids (compound numbers: 120, 121 and 122) showing the highest degree of confidence, more than 99.5%.
Figure 26. The 3D graph shows the predicted and calculated biological activity of the selena steroids (compound numbers: 120, 121 and 122) showing the highest degree of confidence, more than 99.5%.
Marinedrugs 19 00650 g026
Marinedrugs 19 00650 g027 550
Figure 27. Bioactive synthetic tellura steroids.
Figure 27. Bioactive synthetic tellura steroids.
Marinedrugs 19 00650 g027
Marinedrugs 19 00650 g028 550
Figure 28. The 3D graph shows the predicted and calculated biological activity of the tellura steroid (129) showing the highest degree of confidence, more than 99.5%. This tellura steroid is interesting, in that it is a rare case when any chemical compound shows simultaneously such activities as prevention and treatment of neurodegenerative diseases Alzheimer’s and Parkinson’s with strong confidence, over 94 percent. In addition, this steroid demonstrated antioxidant and antihypercholesterolemic activities, and can also be used as a potential drug for the treatment of atherosclerosis. The maximum values of various biological activities are shown in red.
Figure 28. The 3D graph shows the predicted and calculated biological activity of the tellura steroid (129) showing the highest degree of confidence, more than 99.5%. This tellura steroid is interesting, in that it is a rare case when any chemical compound shows simultaneously such activities as prevention and treatment of neurodegenerative diseases Alzheimer’s and Parkinson’s with strong confidence, over 94 percent. In addition, this steroid demonstrated antioxidant and antihypercholesterolemic activities, and can also be used as a potential drug for the treatment of atherosclerosis. The maximum values of various biological activities are shown in red.
Marinedrugs 19 00650 g028
Marinedrugs 19 00650 g029 550
Figure 29. Biological active synthetic astatosteroids.
Figure 29. Biological active synthetic astatosteroids.
Marinedrugs 19 00650 g029
Marinedrugs 19 00650 g030 550
Figure 30. The 3D graph shows the predicted and calculated biological activity of the astatosteroid (133) showing the highest degree of confidence, more than 97.6%. Moreover, it can also be used as a potential drug for the treatment of bone diseases.
Figure 30. The 3D graph shows the predicted and calculated biological activity of the astatosteroid (133) showing the highest degree of confidence, more than 97.6%. Moreover, it can also be used as a potential drug for the treatment of bone diseases.
Marinedrugs 19 00650 g030
Table
Table 1. Biological activities of aromatic steroids with over 90% confidence.
Table 1. Biological activities of aromatic steroids with over 90% confidence.
No.Discovered Activity, (Pa) *Reported ActivityReferences
1Ovulation inhibitor (0.942)
Cardiovascular analeptic (0.924)
Antihypercholesterolemic (0.871)
Lipid metabolism regulator (0.730)		Inhibitor aromatase
Sulfatase inhibitor
Estrogenic
Promotor breast cancer 		[81,82,83,84]
2Antihypercholesterolemic (0.904)
Ovulation inhibitor (0.889)
Neuroprotector (0.870)
Anesthetic general (0.868)
Acute neurologic disorders treatment (0.793)
Prostate disorders treatment (0.729)
Anti-inflammatory (0.713)		Antioxidant
Anti-inflammatory
Uterotrophic
RNA polymerase
Promoter of breast, ovarian and endometrial cancers
Neuroprotective properties		[81,85,86,87]
3Ovulation inhibitor (0.900)
Acute neurologic disorders treatment (0.822)
Antihypercholesterolemic (0.791)		Estrogenic
Agonist of the ERs
RNA polymerase 		[88,89]
4Antihypercholesterolemic (0.856)
Ovulation inhibitor (0.847)
Cardiovascular analeptic (0.842)
Lipid metabolism regulator (0.788)		Estrogenic
Estrogen agonist		[90,91,92]
5Acute neurologic disorders treatment (0.912)
Male reproductive disfunction treatment (0.847)
Ovulation inhibitor (0.786)
Postmenopausal disorders treatment (0.643)
Antihypercholesterolemic (0.640)
Menopausal disorders treatment (0.579) 		Inhibitor aromatase
Sulfatase inhibitor
Inhibitor of human breast cancer
Concentration
Cardiovascular agent
Postmenopausal disorders		[93,94]
6Antihypercholesterolemic (0.973)
Acute neurologic disorders treatment (0.922)
Lipid metabolism regulator (0.907)
Antithrombotic (0.714)
Ovulation inhibitor (0.662)
Dementia treatment (0.616)
Hypolipemic (0.613)
Male reproductive disfunction treatment (0.587)
Menopausal disorders treatment (0.582)		Estrogenic
Ovarian activity
Urine production 		[95]
7Ovulation inhibitor (0.956)
Cardiovascular analeptic (0.927)
Antihypercholesterolemic (0.868)
Male reproductive disfunction treatment (0.847)
Menopausal disorders treatment (0.842)
Acute neurologic disorders treatment (0.745)
Lipid metabolism regulator (0.701)
Menstruation disorders treatment (0.639)
Postmenopausal disorders treatment (0.605)
Muscular dystrophy treatment (0.601)
Contraceptive female (0.570)
Anti-infertility, female (0.567)		Estrogenic
Antiestrogenic effects
Anticancer		[96,97,98]
8Ovulation inhibitor (0.930)
Cardiovascular analeptic (0.925)
Antihypercholesterolemic (0.855)
Male reproductive disfunction treatment (0.843)
Acute neurologic disorders treatment (0.780)
Menopausal disorders treatment (0.747)
Lipid metabolism regulator (0.601)
Muscular dystrophy treatment (0.579)
Postmenopausal disorders treatment (0.561)
Menstruation disorders treatment (0.533) 		Estrogenic
Strongest neuroprotective effect
UDP-glucuronosyltransferase
Anti-breast cancer		[99,100,101]
9Ovulation inhibitor (0.953)
Cardiovascular analeptic (0.928)
Antihypercholesterolemic (0.857)
Menopausal disorders treatment (0.807)
Male reproductive disfunction treatment (0.805)
Acute neurologic disorders treatment (0.660)
Contraceptive (0.655)
Lipid metabolism regulator (0.645)
Contraceptive female (0.558)
Menstruation disorders treatment (0.542)
Anti-infertility, female (0.503)
Postmenopausal disorders treatment (0.500)		Antioxidant
Estrogenic
Anti-breast cancer		[102]
10Ovulation inhibitor (0.925)
Cardiovascular analeptic (0.922)
Antihypercholesterolemic (0.833)
Male reproductive disfunction treatment (0.821)
Menopausal disorders treatment (0.712)
Acute neurologic disorders treatment (0.662)
Contraceptive (0.602)
Lipid metabolism regulator (0.571)
Muscular dystrophy treatment (0.548) 		Estrogenic
Proliferation of human breast cancer		[103,104,105]
11Antihypercholesterolemic (0.959)
Hypolipemic (0.808)		Activity not studied
12Lipid metabolism regulator (0.913)
Antihypercholesterolemic (0.767)		Activity not studied
13Antihypercholesterolemic (0.961)
Hypolipemic (0.711)		Activity not studied
14Antihypercholesterolemic (0.953)Activity not studied
15Antihypercholesterolemic (0.946)Activity not studied
16Antihypercholesterolemic (0.907)Activity not studied
17Antihypercholesterolemic (0.929)Activity not studied
18Antihypercholesterolemic (0.935)Activity not studied
19Antihypercholesterolemic (0.950)Activity not studied
20Antihypercholesterolemic (0.914)Anticancer[52]
* Only activities with Pa > 0.5 are shown.
Table
Table 2. Predicted biological activities of steroid phosphate esters.
Table 2. Predicted biological activities of steroid phosphate esters.
No.Lipid Metabolism Regulators, (Pa) *Reported ActivityRef.
21Wound healing agent (0.975)
Hepatoprotectant (0.961)
Analeptic (0.952)
Antihypercholesterolemic (0.926)
Cholesterol synthesis inhibitor (0.799)		Activity not studied
22Wound healing agent (0.947)
Analeptic (0.941)
Hepatoprotectant (0.932)
Anticarcinogenic (0.915)
Antihypercholesterolemic (0.912)
Cholesterol synthesis inhibitor (0.778)		Activity not studied
23Antihypercholesterolemic (0.900)
Hepatoprotectant (0.853)
Wound healing agent (0.844)
Antineoplastic (0.816)
Antiinflammatory (0.782)
Cholesterol synthesis inhibitor (0.778)
Atherosclerosis treatment (0.675)		Activity not studied
24Neuroprotector (0.987)
Anesthetic general (0.959)
Respiratory analeptic (0.944)
Antihypercholesterolemic (0.909)		Substrate for phosphatases[112]
25Anesthetic general (0.991)
Respiratory analeptic (0.990)
Neuroprotector (0.976)
Antiinflammatory (0.906)
Antihypercholesterolemic (0.900)		Increases blood sugar levels[113]
26Respiratory analeptic (0.979)
Anesthetic general (0.973)
Neuroprotector (0.972)
Antihypercholesterolemic (0.971)
Wound healing agent (0.913)
Antineoplastic (0.826)
Cholesterol synthesis inhibitor (0.801)		Stabilizes blood pressure[114]
27Respiratory analeptic (0.995)
Anesthetic general (0.948)
Antihypercholesterolemic (0.945)
Neuroprotector (0.932)
Hemostatic (0.910)
Wound healing agent (0.897)
Cholesterol synthesis inhibitor (0.867)
Acute neurologic disorders treatment (0.827)		Reduces cholesterol levels[116]
28Antihypercholesterolemic (0.967)
Wound healing agent (0.921)
Neuroprotector (0.909)
Cholesterol synthesis inhibitor (0.872)		Reduces cholesterol levels[116]
29Antihypercholesterolemic (0.996)
Cholesterol absorption inhibitor (0.976) Cholesterol synthesis inhibitor (0.952)
Lipid metabolism regulator (0.952)
Lipoprotein disorders treatment (0.893)		Cholesterol biosynthesis inhibitor[117]
30Antihypercholesterolemic (0.999)
Antihyperlipoproteinemic (0.986)
Hypolipemic (0.974)
Cholesterol absorption inhibitor (0.957)
Lipid metabolism regulator (0.954)
Cholesterol synthesis inhibitor (0.916)
Lipoprotein disorders treatment (0.782)
Acute neurologic disorders treatment (0.751)
Atherosclerosis treatment (0.729)		Cholesterol biosynthesis inhibitor[117]
31Neuroprotector (0.982)
Anesthetic general (0.931)
Antihypercholesterolemic (0.909)
Acute neurologic disorders treatment (0.831)
Prostate disorders treatment (0.640) 		Remedy for the treatment of prostate cancer[118]
* Only activities with Pa > 0.5 are shown.
Table
Table 3. Predicted biological activities of secosteroids.
Table 3. Predicted biological activities of secosteroids.
No.Discovered Activity, (Pa) *Reported ActivityRef.
32Antihypercholesterolemic (0.912)
Hypolipemic (0.802)
Atherosclerosis treatment (0.643)
Antiparkinsonian, rigidity relieving (0.562)		Activity not studied
33Antihypercholesterolemic (0.905)
Hypolipemic (0.753)
Atherosclerosis treatment (0.559)		Activity not studied
34Antihypercholesterolemic (0.908)
Antineoplastic (0.785)
Hypolipemic (0.764)
Apoptosis agonist (0.747)
Cholesterol synthesis inhibitor (0.744)		Anticancer [131]
35Antihypercholesterolemic (0.916)
Antineoplastic (0.833)
Hypolipemic (0.827)
Apoptosis agonist (0.771)
Cholesterol synthesis inhibitor (0.685)
Atherosclerosis treatment (0.633)		Anticancer[131]
36Antihypercholesterolemic (0.904)
Hypolipemic (0.767)
Antineoplastic (0.743)
Apoptosis agonist (0.676)
Proliferative diseases treatment (0.625)
Atherosclerosis treatment (0.539)		Anticancer[133]
37Antihypercholesterolemic (0.915)
Lipid metabolism regulator (0.768)		Activity not studied
38Antihypercholesterolemic (0.909)
Hypolipemic (0.786)		Anticancer[147]
39Antiparkinsonian, rigidity relieving (0.960)
Hyperparathyroidism treatment (0.892)
Antihypercholesterolemic (0.845)
Hypolipemic (0.790)
Atherosclerosis treatment (0.628)		Calcium and phosphates metabolism regulator[148]
40Chemopreventive (0.989)
Hepatoprotectant (0.986)
Respiratory analeptic (0.978)
Antihypercholesterolemic (0.977)
Proliferative diseases treatment (0.969)
Antimycobacterial (0.939)
Neuroprotector (0.895)
Antineoplastic (0.874)
Antiprotozoal (Leishmania) (0.772)
Atherosclerosis treatment (0.601)
Neurodegenerative diseases treatment (0.590)
Alzheimer’s disease treatment (0.570)		Activity not studied
previously
* Only activities with Pa > 0.5 are shown.
Table
Table 4. Predicted biological activities of α,β-epoxy steroids.
Table 4. Predicted biological activities of α,β-epoxy steroids.
No.Discovered Activity, (Pa) *Reported ActivityRef.
41Apoptosis agonist (0.950)
Antihypercholesterolemic (0.931)
Antineoplastic (0.886)
Antieczematic (0.842)
Atherosclerosis treatment (0.712)		Cytotoxic[160]
42Apoptosis agonist (0.950)
Antihypercholesterolemic (0.931)
Antineoplastic (0.886)
Antieczematic (0.842)
Atherosclerosis treatment (0.712)		Cytotoxic[160]
43Apoptosis agonist (0.954)
Antineoplastic (0.914)
Antihypercholesterolemic (0.906)
Atherosclerosis treatment (0.741)		Activity not studied
44Antihypercholesterolemic (0.934)
Apoptosis agonist (0.929)
Hypolipemic (0.864)
Antineoplastic (0.861) 		Activity not studied
45Hepatoprotectant (0.994)
Respiratory analeptic (0.990)
Antihypercholesterolemic (0.897)		Activity not studied
46Antihypercholesterolemic (0.900)
Neuroprotector (0.749)
Cholesterol synthesis inhibitor (0.636)		Activity not studied
47Antihypercholesterolemic (0.901)
Lipid metabolism regulator (0.833)
Prostate disorders treatment (0.714)		Anticancer[165]
48Antihypercholesterolemic (0.924)
Lipid metabolism regulator (0.820)
Neuroprotector (0.728)		Anticancer[165]
* Only activities with Pa > 0.5 are shown.
Table
Table 5. Biological activities of endoperoxy steroids.
Table 5. Biological activities of endoperoxy steroids.
No.Lipid Metabolism Regulators, (Pa) *Reported ActivityRef.
49Antihypercholesterolemic (0.914)
Hypolipemic (0.635)		Activity not studied
50Atherosclerosis treatment (0.911)
Hypolipemic (0.836)
Lipoprotein disorders treatment (0.826)
Antihypercholesterolemic (0.802)		Activity not studied
51Atherosclerosis treatment (0.907)
Antihypercholesterolemic (0.788)		Activity not studied
52Atherosclerosis treatment (0.919)
Hypolipemic (0.822)
Lipoprotein disorders treatment (0.814)		Activity not studied
53Antihypercholesterolemic (0.926)
Hypolipemic (0.800)
Atherosclerosis treatment (0.709)		Activity not studied
54Antihypercholesterolemic (0.900)
Hypolipemic (0.827)
Atherosclerosis treatment (0.659) Hyperparathyroidism treatment (0.502)		Activity not studied
55Antihypercholesterolemic (0.917)
Hypolipemic (0.786)		Anticancer [183]
56Antihypercholesterolemic (0.917)
Atherosclerosis treatment (0.858)
Hypolipemic (0.786)		Anticancer [183]
* Only activities with Pa > 0.5 are shown.
Table
Table 6. Predicted biological activities of hydroperoxy steroids.
Table 6. Predicted biological activities of hydroperoxy steroids.
No.Discovered Activity, (Pa) *Reported ActivityRef.
57Antihypercholesterolemic (0.905)
Cholesterol synthesis inhibitor (0.799)		Activity not studied
58Antihypercholesterolemic (0.905)
Hypolipemic (0.802)
Cholesterol synthesis inhibitor (0.621)
Atherosclerosis treatment (0.542)		Activity not studied
59Antihypercholesterolemic (0.933)
Hypolipemic (0.877)
Cholesterol synthesis inhibitor (0.644)
Atherosclerosis treatment (0.675)
Prostate disorders treatment (0.645)		Cytotoxic [186]
60Antihypercholesterolemic (0.933)
Hypolipemic (0.877)
Antineoplastic (0.835)
Cholesterol synthesis inhibitor (0.650)
Atherosclerosis treatment (0.554)		Cytotoxic [186]
61Antihypercholesterolemic (0.922)
Hypolipemic (0.868)
Atherosclerosis treatment (0.678)
Antiparkinsonian, rigidity relieving (0.516)		Activity not studied
62Antihypercholesterolemic (0.913)
Antineoplastic (0.802)
Hypolipemic (0.795)		Hepatoprotective Cytotoxic [191]
63Antihypercholesterolemic (0.933)
Hypolipemic (0.877)
Cholesterol synthesis inhibitor (0.644)		Activity not studied
64Antihypercholesterolemic (0.923)
Hypolipemic (0.774)
Cholesterol synthesis inhibitor (0.604)
Biliary tract disorders treatment (0.577)		Activity not studied
65Antihypercholesterolemic (0.918)
Hypolipemic (0.779)
Biliary tract disorders treatment (0.655)		Antiproliferative [194]
66Antihypercholesterolemic (0.930)
Hypolipemic (0.767)
Biliary tract disorders treatment (0.717)
Atherosclerosis treatment (0.590)		Activity not studied
* Only activities with Pa > 0.5 are shown.
Table
Table 7. Predicted biological activities of CBS steroids.
Table 7. Predicted biological activities of CBS steroids.
No.Discovered Activity, (Pa) *Reported ActivityRef.
67Antihypercholesterolemic (0.902)
Hypolipemic (0.721)
Cholesterol synthesis inhibitor (0.534)		Activity not studied
68Antihypercholesterolemic (0.932)
Hypolipemic (0.695)
Cholesterol synthesis inhibitor (0.588)		Activity not studied
69Antineoplastic (0.915)
Antihypercholesterolemic (0.900)
Hypolipemic (0.897)
Apoptosis agonist (0.892)
Antineoplastic (liver cancer) (0.822)
Chemopreventive (0.776)
Atherosclerosis treatment (0.690)
Cytoprotectant (0.611)
Prostate cancer treatment (0.557)
Antimetastatic (0.528) 		Cytotoxic[206]
70Antihypercholesterolemic (0.953)
Hypolipemic (0.758)
Lipid metabolism regulator (0.674)
Atherosclerosis treatment (0.513)		Antifungal[207]
71Antihypercholesterolemic (0.939)
Hypolipemic (0.746)
Lipid metabolism regulator (0.599)		No activity detected[207]
72Antihypercholesterolemic (0.923)
Hypolipemic (0.732)
Atherosclerosis treatment (0.643)
Cholesterol synthesis inhibitor (0.640)		Activity not studied
73Hypolipemic (0.900)
Atherosclerosis treatment (0.689)
Cholesterol synthesis inhibitor (0.671)
Antihypercholesterolemic (0.662)
Lipid metabolism regulator (0.529)		 Activity not studied
74Antihypercholesterolemic (0.964)
Hypolipemic (0.849)
Antineoplastic (0.849)
Antihyperlipoproteinemic (0.801)
Cholesterol synthesis inhibitor (0.671)
Atherosclerosis treatment (0.610)
Prostate cancer treatment (0.601)		Cytotoxic
Anticancer		[211,212,213,214]
75Antihypercholesterolemic (0.923)
Hypolipemic (0.732)
Atherosclerosis treatment (0.643)
Cholesterol synthesis inhibitor (0.640)		Activity not studied
76Antihypercholesterolemic (0.935)
Hypolipemic (0.731)
Antihyperlipoproteinemic (0.689)
Cholesterol synthesis inhibitor (0.600)		Activity not studied
77Antihypercholesterolemic (0.908)
Hypolipemic (0.726)
Cholesterol synthesis inhibitor (0.589)
Antihyperlipoproteinemic (0.587)		Activity not studied
78Antihypercholesterolemic (0.969)
Hypolipemic (0.810)
Lipid metabolism regulator (0.716)
Cholesterol synthesis inhibitor (0.707)
Atherosclerosis treatment (0.586)		Activity not studied
* Only activities with Pa > 0.5 are shown.
Table
Table 8. Biological activities of neo steroids.
Table 8. Biological activities of neo steroids.
No.Discovered Activity, (Pa) *Reported ActivityRef.
79Antihypercholesterolemic (0.964)
Atherosclerosis treatment (0.717)		Activity not studied
80Antihypercholesterolemic (0.956)Activity not studied
81Antihypercholesterolemic (0.989)
Hypolipemic (0.808)		Activity not studied
82Antihypercholesterolemic (0.960)
Atherosclerosis treatment (0.683)		Activity not studied
83Antihypercholesterolemic (0.961)
Cholesterol synthesis inhibitor (0.745)		Activity not studied
84Antihypercholesterolemic (0.956)
Cholesterol synthesis inhibitor (0.747)		Activity not studied
85Antihypercholesterolemic (0.964)Activity not studied
86Antihypercholesterolemic (0.969)Activity not studied
87Antihypercholesterolemic (0.952)
Atherosclerosis treatment (0.710)		Activity not studied
88Antihypercholesterolemic (0.965)
Atherosclerosis treatment (0.677)		Activity not studied
89Antihypercholesterolemic (0.969)Activity not studied
90Antihypercholesterolemic (0.965)
Atherosclerosis treatment (0.700)		Activity not studied
91Antihypercholesterolemic (0.969)Activity not studied
92Antihypercholesterolemic (0.962)
Atherosclerosis treatment (0.704)
Lipid metabolism regulator (0.702)		Activity not studied
93Antihypercholesterolemic (0.974)
Antimicrobial treatment (0.717)		Antimicrobial [237]
94Antihypercholesterolemic (0.961)
Antineoplastic (0.863)
Anticarcinogenic (0.828)
Lipid metabolism regulator (0.747)
Antimetastatic (0.590)		Anticancer [238,239]
95Antihypercholesterolemic (0.936)
Antineoplastic (0.870)
Anticarcinogenic (0.807)
Antimetastatic (0.598)		Anticancer [238,239]
* Only activities with Pa > 0.5 are shown.
Table
Table 9. Biological activities of soft coral steroids.
Table 9. Biological activities of soft coral steroids.
No.Discovered Activity, (Pa) *Reported ActivityRef.
96Neuroprotector (0.983)
Antihypercholesterolemic (0.919)
Acute neurologic disorders treatment (0.636)
Hypolipemic (0.626)		Anticancer [243]
97Antihypercholesterolemic (0.954)
Neuroprotector (0.754)
Hypolipemic (0.704)		Activity not studied
98Antihypercholesterolemic (0.927)
Neuroprotector (0.773)
Hypolipemic (0.584)		Activity not studied
99Antihypercholesterolemic (0.962)Activity not studied
100Antihypercholesterolemic (0.918)
Anti-inflammatory (0.903)
Antineoplastic (0.875)
Proliferative diseases treatment (0.856)
Atherosclerosis treatment (0.618)		Anti-inflammatory
Anticancer		[247]
101Antihypercholesterolemic (0.976)
Hypolipemic (0.735)
Lipid metabolism regulator (0.707)		Activity not studied
102Antihypercholesterolemic (0.920)
Hypolipemic (0.798)
Atherosclerosis treatment (0.637)
Hyperparathyroidism treatment (0.523)		Activity not studied
103Antihypercholesterolemic (0.955)
Atherosclerosis treatment (0.596)		Activity not studied
104Proliferative diseases treatment (0.967)
Chemopreventive (0.958)
Antihypercholesterolemic (0.947)
Anticarcinogenic (0.907)
Antineoplastic (0.902)
Hypolipemic (0.781)
Atherosclerosis treatment (0.609)		Anticancer[251]
105Antihypercholesterolemic (0.957)
Hypolipemic (0.809)
Atherosclerosis treatment (0.592)		Activity not studied
106Antihypercholesterolemic (0.955)
Hypolipemic (0.878)
Atherosclerosis treatment (0.658)		Activity not studied
107Neuroprotector (0.938)
Antihypercholesterolemic (0.912)
Atherosclerosis treatment (0.548)		Activity not studied
* Only activities with Pa > 0.5 are shown.
Table
Table 10. Biological activities of epithio steroids.
Table 10. Biological activities of epithio steroids.
No.Discovered Activity, (Pa) *Reported ActivityRef.
108Antineoplastic (0.964)
Antisecretoric (0.948)
Estrogen antagonist (0.860)
Cardiotonic (0.729)
Prostate disorders treatment (0.709)
Neuroprotector (0.723)
Bone diseases treatment (0.693)
Antineoplastic (breast cancer) (0.598)		Anti-breast cancer
Estrogen receptor antagonist		[294]
109Antineoplastic (0.966)
Antisecretoric (0.952)
Estrogen antagonist (0.832)
Anti-inflammatory (0.754)
Prostate disorders treatment (0.736)
Prostatic (benign) hyperplasia treatment (0.673)		Estrogen antagonist[294]
110Antineoplastic (0.966)
Antisecretoric (0.952)
Estrogen antagonist (0.832)
Anti-inflammatory (0.754)
Prostate disorders treatment (0.736)
Prostatic (benign) hyperplasia treatment (0.673)		Estrogen antagonist[294]
111Antineoplastic (0.932)
Antihypercholesterolemic (0.759)
Bone diseases treatment (0.729)
Hypolipemic (0.676)
Estrogen antagonist (0.660)		Anabolic[294]
112Antisecretoric (0.967)
Estrogen antagonist (0.946)
Antineoplastic (0.939)
Anabolic (0.823)		Anabolic[284,285,286]
113Cholesterol antagonist (0.933)
Antihypercholesterolemic (0.929)
Hypolipemic (0.818)
Estrogen antagonist (0.443)		Antiseptic,
Germicidal,
Fungicidal		[294]
114Cholesterol antagonist (0.946)
Antihypercholesterolemic (0.930)
Hypolipemic (0.781)
Estrogen antagonist (0.465)		Antiseptic,
Germicidal,
Fungicidal		[294]
115Cholesterol antagonist (0.932)
Antihypercholesterolemic (0.900)
Cardiotonic (0.886)
Choleretic (0.871)
Atherosclerosis treatment (0.838)
Antineoplastic (0.775)
Hypolipemic (0.746)
Estrogen antagonist (0.611)		DOCA inhibitor[294]
116Lipid metabolism regulator (0.954)
Antineoplastic (0.924)
Apoptosis agonist (0.869)
Estrogen antagonist (0.505)		Anticancer [292,295]
117Cholesterol antagonist (0.916)
Antihypercholesterolemic (0.836)
Hypolipemic (0.801)		Activity not studied
* Only activities with Pa > 0.5 are shown.
Table
Table 11. Biological activities of the selena steroids.
Table 11. Biological activities of the selena steroids.
No.Discovered Activity, (Pa) *Reported ActivityRef.
118Antihypercholesterolemic (0.905)Activity not studied
119Choleretic (0.909)
Antihypercholesterolemic (0.905)		Activity not studied
120Hypolipemic (0.995)
Atherosclerosis treatment (0.991)
Lipoprotein disorders treatment (0.982)
Antioxidant (0.973)
Erythropoiesis stimulant (0.823)
Biliary tract disorders treatment (0.808)
Laxative (0.709)		Activity not studied
121Hypolipemic (0.995)
Atherosclerosis treatment (0.989)
Lipoprotein disorders treatment (0.980)
Antioxidant (0.970)
Biliary tract disorders treatment (0.808)
Erythropoiesis stimulant (0.730)
Laxative (0.683)		Activity not studied
122Hypolipemic (0.996)
Atherosclerosis treatment (0.995)
Lipoprotein disorders treatment (0.991)
Antioxidant (0.978)
Erythropoiesis stimulant (0.756)		Activity not studied
123Hypolipemic (0.913)
Antihypercholesterolemic (0.884)
Atherosclerosis treatment (0.822)		Activity not studied
124Antihypercholesterolemic (0.902)
Hypolipemic (0.899)
Atherosclerosis treatment (0.791)		Activity not studied
125Antihypercholesterolemic (0.905)Activity not studied
126Antihypercholesterolemic (0.908)
Bone diseases treatment (0.772)
Hypolipemic (0.769)		Activity not studied
127Antihypercholesterolemic (0.912)
Antineoplastic (0.884)
Anticarcinogenic (0.753)		Cytotoxic activity
Agent for Alzheimer’s
disease		[303,310]
128Antihypercholesterolemic (0.953)
Antineoplastic (0.856)
Anticarcinogenic (0.804)		Cytotoxic activity
Agent for Alzheimer’s
disease		[303,310]
* Only activities with Pa > 0.5 are shown.
Table
Table 12. Biological activities of tellura steroids.
Table 12. Biological activities of tellura steroids.
No.Discovered Activity, (Pa) *Reported Activity
129Atherosclerosis treatment (0.977)
Antioxidant (0.963)
Antihypercholesterolemic (0.956)
Antiparkinsonian (0.955)
Neurodegenerative diseases treatment (0.954)
Alzheimer’s disease treatment (0.940)
Antihyperlipoproteinemic (0.811)		Activity not studied
130Antihypercholesterolemic (0.958)
Atherosclerosis treatment (0.890)
Alzheimer’s disease treatment (0.838)
Antioxidant (0.807)
Neurodegenerative diseases treatment (0.801)		Activity not studied
131Antioxidant (0.922)
Atherosclerosis treatment (0.908)
Neurodegenerative diseases treatment (0.877) Antihypercholesterolemic (0.869)
Alzheimer’s disease treatment (0.868)
Antiparkinsonian (0.848)		Activity not studied
132Antihypercholesterolemic (0.909)
Atherosclerosis treatment (0.876)
Alzheimer’s disease treatment (0.828)
Neurodegenerative diseases treatment (0.808)
Biliary tract disorders treatment (0.807)		Activity not studied
* Only activities with Pa > 0.5 are shown.
Table
Table 13. Biological activities of astatosteroids.
Table 13. Biological activities of astatosteroids.
No.Discovered Activity, (Pa) *Reported Activity
133Antihypercholesterolemic (0.967)
Antineoplastic (0.824)
Bone diseases treatment (0.796)
Hypolipemic (0.785)
Neuroprotector (0.758)
Antipsoriatic (0.739)
Anti-inflammatory (0.728)
Apoptosis agonist (0.724)
Prostate disorders treatment (0.719)		Activity not studied
134Antihypercholesterolemic (0.927)
Bone diseases treatment (0.784)
Hypolipemic (0.740) 		Activity not studied
135Antihypercholesterolemic (0.920)
Growth stimulant (0.805)
Bone diseases treatment (0.743)		Activity not studied
136Antihypercholesterolemic (0.901)
Bone diseases treatment (0.720)
Growth stimulant (0.703)		Activity not studied
137Antihypercholesterolemic (0.912)
Bone diseases treatment (0.777) 		Activity not studied
* Only activities with Pa > 0.5 are shown.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Dembitsky, V.M. In Silico Prediction of Steroids and Triterpenoids as Potential Regulators of Lipid Metabolism. Mar. Drugs 2021, 19, 650. https://doi.org/10.3390/md19110650

AMA Style

Dembitsky VM. In Silico Prediction of Steroids and Triterpenoids as Potential Regulators of Lipid Metabolism. Marine Drugs. 2021; 19(11):650. https://doi.org/10.3390/md19110650

Chicago/Turabian Style

Dembitsky, Valery M. 2021. "In Silico Prediction of Steroids and Triterpenoids as Potential Regulators of Lipid Metabolism" Marine Drugs 19, no. 11: 650. https://doi.org/10.3390/md19110650

APA Style

Dembitsky, V. M. (2021). In Silico Prediction of Steroids and Triterpenoids as Potential Regulators of Lipid Metabolism. Marine Drugs, 19(11), 650. https://doi.org/10.3390/md19110650

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop